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Abstract 
 
Background. Intestinal failure (IF) is characterized by the reduced capacity of the 
intestine to digest and absorb nutrients and fluids required for the maintenance of 
energy, fluid, electrolyte, and micronutrient balance, as well as normal growth and 
development in children. In these studies, IF was defined by over 50% resection of 
small bowel and/or duration of parenteral nutrition (PN) over 30 days. Patients with IF 
are at risk for multiple potentially life-threatening complications, including IF-
associated liver disease (IFALD). 
 
Aims. To study the incidence of long-term PN and associated liver disease, 
characterize liver histopathology, and evaluate risk factors of IFALD during and after 
weaning off PN in pediatric onset IF.  
 
Methods. Long-term effects of IF and PN on serum non-cholesterol sterols, including 
plant sterols and cholesterol precursor sterols, and liver biochemistry were evaluated 
prospectively in a single-centre (patients n=11) and a nation-wide study (patients 
n=39). Liver histology, risk factors of IFALD, and serum fibroblast growth factor 21 
(FGF21) were studied in two cross-sectional studies (patients n=38 and n=35). 
 
Results. During PN, serum plant sterol levels were significantly increased in 
neonates and children with IF compared to healthy controls (P<0.05 for all). In 
children, total and individual serum plant sterol levels associated with percentage of 
parenteral calories (r=0.70-0.92, P<0.05 for all), and reflected their distribution in PN 
lipid emulsions. In neonates, total duration of PN associated with serum cholestanol, 
stigmasterol, avenasterol, ALT, and AST (r=0.472-0.636, P<0.05). In neonates with 
IFALD, serum plant sterols ratios to cholesterol, especially stigmasterol, were 
increased compared with healthy controls, neonates without IFALD and children on 
PN (P<0.005 for all). After weaning off PN, IFALD persisted in 25% of neonates with 
4.2- and 2.2-times higher serum stigmasterol and cholestanol ratios to cholesterol 
compared with neonates without IFALD (P<0.05).  
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Abnormal liver histology was found in 94% of IF patients on PN and 77% of patients 
weaned off PN (P=0.370). During PN, liver histology was weighted with cholestasis 
(38% of patients on PN vs. 0% of patients weaned off PN, P=0.003) and portal 
inflammation (38% vs. 9%, P=0.05). After weaning off PN, cholestasis resolved, but 
significant fibrosis (88% vs. 64%, P=0.143) and steatosis (50% vs. 45%, P=1.000) 
persisted. Fibrosis stage was associated with remaining small bowel length (r=-
0.486, P=0.002), duration of PN (r=0.387, P=0.016), and number of septic episodes 
(r=0.480, P=0.002). In a multivariate analysis, age-adjusted small bowel length (ß=-
0.553, P=0.001), portal inflammation (ß=0.291, P=0.030), and absence of ileocaecal 
valve (ß=0.267, P=0.048) were predictive for fibrosis stage.  
 
IF patients with steatosis had markedly higher serum FGF21 concentration (median 
626 vs. 108 pg/mL, P=0.002) and more advanced liver fibrosis (Metavir stage median 
1.6 vs. 0.7, P=0.020) compared to those without steatosis. Serum FGF21 correlated 
with steatosis grade (r=0.589, P=0.001). Hepatic steatosis and serum FGF21 
associated with duration of PN (r=0.471-0.580) and remaining small bowel length (r=-
0.368- -0.502, p<0.05 for all). Liver steatosis grade (ß=0.630, P=0.001) predicted 
serum FGF21 concentration in a multivariate regression model.  
 
Conclusions. During PN, serum plant sterol levels are high and reflect their 
distribution in PN lipid emulsions. In neonates, IFALD is frequent and associates with 
markedly increased serum plant sterols compared to healthy neonatal controls and 
children on PN with more mature liver function. After weaning off PN, serum 
stigmasterol and cholestanol remain high in neonates with persistent IFALD. 
 
Liver histology is characterized by cholestasis, portal inflammation, liver fibrosis and 
steatosis in IF patients on PN. After weaning off PN, portal inflammation diminishes 
and cholestasis resolves, but fibrosis and steatosis persists. In addition to duration of 
PN, extensive small intestinal resection and loss of ileocaecal valve as well as septic 
episodes are major risk factors of histological liver fibrosis. Increased serum FGF21 
levels reflect the presence and the degree of liver steatosis in patients with pediatric 
onset IF.  
 9 
List of original publications 
 
This thesis is based on the following publications: 
 
I. Kurvinen A, Nissinen MJ, Gylling H, Miettinen TA, Lampela H, Koivusalo AI, 
Rintala RJ, Pakarinen MP. Effects of long-term parenteral nutrition on serum 
lipids, plant sterols, cholesterol metabolism, and liver histology in pediatric 
intestinal failure. J Pediatr Gastroenterol Nutr 2011;53:440-446. 
 
II. Kurvinen A, Nissinen MJ, Andersson S, Korhonen P, Ruuska T, Taimisto M, 
Kalliomäki M, Lehtonen L, Sankilampi U, Arikoski P, Saarela T, Miettinen TA, 
Gylling H, Pakarinen MP. Parenteral plant sterols and intestinal failure-
associated liver disease in neonates. J Pediatr Gatroenterol Nutr 2012;54:803-
811. 
 
III. Mutanen A, Lohi J, Heikkilä P, Koivusalo AI, Rintala RJ, Pakarinen MP. 
Persistent abnormal liver fibrosis after weaning off parenteral nutrition in 
pediatric intestinal failure. Hepatology 2013;58:729-738. 
 
IV. Mutanen A, Heikkilä P, Lohi J, Raivio T, Jalanko H, Pakarinen MP. Serum 
FGF21 increases with hepatic fat accumulation in pediatric onset intestinal 
failure. J Hepatol 2014;60:183-190. 
 
The publications are referred to in the text by their Roman numerals and are 
reprinted here with the permission of the publisher. In addition some unpublished 
data are presented. 
 
 10 
Abbreviations 
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1 Introduction 
 
Intestinal failure (IF) is characterized by the reduced capacity of the intestine to 
digest and absorb nutrients and fluids required for the maintenance of energy, fluid, 
electrolyte, and micronutrient balance as well as normal growth and development in 
children (Goulet O 2006). The most frequent causes of IF are short bowel syndrome 
(SBS) and intestinal motility disorders requiring long-term parenteral nutrition (PN) 
(Goulet O 2004). IF affects patients in all age groups from neonates to elderly with 
different etiologies in different ages. Congenital conditions, including necrotizing 
enterocolitis (NEC), gastroschisis, small bowel atresia (SBA), and midgut volvulus, 
cause neonatal IF requiring long-term medical and nutritional care (Finkel Y 2008). In 
children, IF most commonly results from midgut volvulus while mesenteric ischemia 
and Crohn’s disease are among the leading causes in adults (Goulet O 2006, Pironi 
L 2006).  
 
The development of PN in the 1960s led to significant improvements in the survival of 
IF patients (Wilmore DW 1968). More recent advances, including improved catheter 
care, awareness and aggressive treatment of septic episodes and small intestinal 
bacterial overgrowth (SIBO), new surgical approaches and improvements in enteral 
and parenteral nutrition, have significantly changed the treatment and improved 
outcomes of IF patients (Kelly DA 2006). Intestinal and multivisceral transplantation 
has become a treatment option to those with most severe and irreversible forms of IF 
(Fishbein TM 2006). Referral to multidisciplinary specialized IF treatment teams, 
including surgeons, gastroenterologists, nurses, and dieticians, has steadily shown to 
improve patient outcomes, including survival and quality of life (Sudan D 2005, Modi 
BP 2008). 
 
Despite these advances in the management of IF, most patients suffer multiple 
complications during the course of the disease. Intestinal failure associated liver 
disease (IFALD) is a major complication and the leading cause of morbidity and 
mortality in pediatric and adult IF patients (Kelly DA 2006, Carter BA 2007, Pironi L 
2012, D’Antiga L 2013). Etiology of IFALD is proposed as multifactorial, including 
duration and composition of PN, different components of PN, such as plant sterols, 
massive intestinal resection, SIBO, septic episodes, prematurity, low birth weight, 
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and lack of enteral nutrients (Beath SV 1996, Clayton PT 1998, Spencer AU 2005, 
Kelly DA 2010, D’Antiga L 2013). PN associated liver disease (PNALD), defined by 
liver biochemistry, occurs in up to 15 to 85% of neonates, children and adults on 
long-term PN (Kelly DA 2006, Pironi L 2012). After weaning off PN, liver biochemistry 
usually slowly normalize but liver histology may remain abnormal or the liver damage 
may even progress, as reported in few small series (Rodgers BM 1976, Dahms BB 
1981, Vileisis RA 1982, Moss RL 1993, Hasegawa T 2002, Pichler J 2010, Yeop I 
2012). Despite the various factors linked to development of IFALD, the exact 
mechanisms causing and maintaining the liver damage remain unknown. The aim of 
this thesis is to study the incidence of long-term PN and IFALD and to characterize 
liver function, risk factors of IFALD, and liver histopathology in neonates, children, 
and young adults with pediatric onset IF.  
 14 
2 Review of the literature 
 
 
2.1 Intestinal failure (IF) 
 
 
2.1.1 History of parenteral nutrition and IF 
 
As early as Egyptian times, liquid formulae, including wine, brandy, whey, and milk, 
were used to improve general health and to treat a range of ailments (Randall HT 
1984). Until the delivery of food directly into the esophagus through a feeding tube 
was described in 1598, rectal infusion of nutrients was the only practical means to 
access the gastrointestinal tract of malnourished patients unable to maintain fluid and 
energy balance per orally (Harkness L 2002, Chernoff R 2006). The next major 
advancement occurred in the early seventeenth century when circulation was 
described by William Harvey and led to growing interest in intravenous administration 
of nutrients (Lagnas A 2008). In the late nineteenth century the first intravenous 
glucose and amino acid infusions were reported, but because of complications and 
limited caloric density, intravenous treatment was not safe (Wretlind A 1992). Until 
the late 1960s malnutrition secondary to IF was an irreversible and fatal condition. In 
1968, Dudrick and Wilmore reported a successful long-term total PN treatment via 
superior vena cava catheter in a child with SBA and IF (Wilmore DW 1968, Dudrick 
SJ 1969). Soon after introduction of successful long-term PN, PN-associated 
complications affecting patient survival and outcome, including liver disease as a 
major complication, were reported (Peden VH 1971, Touloukian RJ 1973, Rager R 
1975).  
 
 
2.1.2 Definition of IF 
 
IF is characterized by reduced capacity of the intestine to digest and absorb nutrients 
and fluids required for maintenance of energy, fluid, electrolyte, and micronutrient 
balance as well as normal growth and development in children (Goulet O 2006). This 
definition remains a matter of debate as various additional definitions have been 
suggested to describe the reduction of functional gut mass in patients with SBS after 
surgical bowel resection and in patients with disease-associated loss of absorption 
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due to intestinal motility disorders or enteropathies (O’Keefe SJ 2006). The definition 
of IF is usually combined with an estimate of absolute and/or percentage of 
remaining small bowel length and amount and/or duration of PN. In children, PN 
duration of over 30 days is often used as a sign of IF (Fitzgibbons SC 2010). The 
degree of IF may be defined according to the amount of PN required (Goulet O 
2004). A massive resection leaving less than 40 cm or 30% of small bowel leads 
more likely to long-term dependence on PN in children (Beath SV 1996, Goulet O 
2004, D’Antiga L 2013). Another approach is to estimate the remaining age-adjusted 
bowel length that takes into account the growth of the bowel (Struijs MC 2009). In 
most children, IF is considered reversible as adaptation may allow the 
discontinuation of PN, while preserving normal growth and development (Goulet O 
2004). Some patients remain partially or totally dependent on PN and are thus 
considered to have irreversible IF (Goulet O 2004). Beside anatomical and nutritional 
criteria for defining IF, actual measurements of intestinal energy and wet weight 
absorption may be used to define IF in adults (Jeppesen PB 2000).  
 
 
2.1.3 Incidence and prevalence of IF 
 
Because of rarity of IF, varying definitions and multifactorial etiology the precise 
incidence and prevalence of IF in children and adults is unknown (Koffeman GI 2003, 
Youssef NN 2012). In adults, a retrospective European multicenter study reported 
estimates on IF incidence rates, expressed as patients/million inhabitants/years and 
defined by newly diagnosed cases of IF on home PN (HPN), ranging from 0.4 in 
Portugal to 3.0 in Netherlands (Bakker H 1999). The same data from European 
countries revealed the prevalence of IF in children over 16 years through adulthood 
to be 0.65 (patients/million inhabitants/year) in Spain, 1.1 in Portugal, 3.0 in Belgium, 
3.6 in France, 3.7 in the United Kingdom and Netherlands, and 12.7 in Denmark 
(Bakker H 1999). Approximately 40 000 adult patients were dependent on HPN in 
1994 in the United States (Howard L 1995). In a more recent study, 16 000 children 
were estimated to be on HPN in the United States (Spencer AU 2008). 
 
In children, the most common type of IF in developed countries is SBS with an 
overall estimated incidence of from 3 up to 25 per 100 000 live births, being higher in 
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premature babies (Wallander J 1992, Guarino A 2003, Schalamon J 2003, Wales 
PW 2004, DeLegge M 2007, Casey L 2008, Wales PW 2010). In premature neonates 
with birth weight under 1500 g the average incidence of SBS was estimated to be 
7/1000 (Cole CR 2008). These numbers are likely to be inaccurate because of ruling 
out IF patients weaned off PN and those with temporary need for PN, and including 
patients with diagnoses other than IF (O’Keefe SJ 2006). (Table 1) 
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2.1.4 Causes of IF in children 
 
The causes of pediatric IF vary according to the specific clinical setting surveyed. 
The etiology of IF can be divided into three categories: SBS, intestinal motility 
disorders, and congenital enteropathies (Fig 1 and Table 2). Moreover, the etiology 
of IF varies in different ages as NEC is the leading cause of IF in premature and/or 
low birth weight neonates while midgut volvulus, post traumatic resection, 
thromboembolic events, and inflammatory bowel disease may lead to IF later in 
childhood. In contrast, in adults SBS represents 75-80%, intestinal motility disorders 
20%, and enteropathies 5% of IF and PN dependency (Bakonyi NA 2004, Pironi L 
2006). In adults, the most common underlying diagnoses of IF are mesenteric 
ischemia and Crohn’s disease. (Pironi L 2006, Goulet O 2006)  
 
 
2.1.4.1 Short bowel syndrome  
 
SBS results from massive resection of the small bowel and leads to malabsorption of 
nutrients, fluid, and electrolytes (Goulet O 2004). SBS is the most common condition 
causing IF (Goulet O 2006). In neonates, NEC is the most common cause of SBS 
(up to 55%), followed by intestinal atresia (10-25%), gastroschisis (13-20%), and 
midgut volvulus (6-14%) (Wales PW 2004, Casey L 2008, Salvia G 2008, Cowles RA 
2010, Gutierrez IM 2011). In older children, SBS can result from midgut volvulus, 
post traumatic resection, thromboembolic events, and inflammatory bowel disease 
(Goulet O 2006). (Figure 2, Table 2) 
 
Necrotizing enterocolitis 
NEC is characterized by inflammatory bowel necrosis and is a major cause of 
mortality and morbidity of preterm infants. The proportion of neonates with NEC is 
significantly higher in preterm babies (born before 37 weeks of gestation) and those 
with low birth weight (under 1500 g) (Cole CR 2008, Navarro F 2009). NEC occurs in 
90% of cases after starting of enteral feeds. Events leading to NEC are described as 
immature intestinal host defense and blood flow regulation, bacterial colonization, 
and inflammatory responses. The inflammatory changes of the bowel in NEC 
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primarily affect terminal ileum and proximal colon, but can also be widespread 
throughout the colon and small intestine. Treatment for NEC includes PN, 
nasogastric decompression, and broad-spectrum antibiotics. In case of perforation, 
persistent intestinal obstruction, deterioration despite maximal medical treatment, or 
development of intestinal stricture surgical treatment is indicated. In cases where 
major small bowel resection is required, infants with NEC will develop IF needing 
long-term PN. (Finkel Y 2008) 
 
Gastroschisis 
Gastroschisis is a congenital malformation characterized by evisceration of the bowel 
through an abdominal wall defect, generally to the right of intact umbilical cord, with 
no membrane covering the bowel. The prevalence of gastroschisis is estimated to be 
up to 4.0 per 10 000 births. Soon after birth, the reduction of the abdominal contents 
is done surgically through the abdominal wall defect and if not possible, a prosthetic 
silo is used. After surgical repair, feeding intolerance and need for long-term PN is 
highly prevalent in infants with gastroschisis caused by a combination of co-
morbidities, including intestinal dysmotility, intestinal atresia (in 10-20% of infants 
with gastroschisis), perforation, and presence of necrotic bowel segments. Enteric 
nervous system damage seen in gastroschisis is suggested to relate on prenatal 
amniotic fluid exposure of the bowel. (Finkel Y 2008, Rodriguez L 2012) 
 
Intestinal atresia 
Intestinal atresia is a congenital malformation in which one or several bowel 
segments, classified according to localization as jejunoileal or colonic atresia, are 
narrow or absent. Multiple atresias may lead to SBS, IF, and need for long-term PN. 
Moreover, infants with intestinal atresia may experience intestinal dysmotility and 
feeding intolerance after surgical resection of the atretic segment and primary 
anastomosis. Delayed maturation of the myenteric plexus, alterations in intestinal 
pacemaker cells of Cajal and smooth muscle cells are suggested to result from fetal 
obstruction impairing development of the enteric nervous system. (Ozguner IF 2005, 
Finkel Y 2008, Dicken BJ 2011) 
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Figure 1. Distribution of diagnoses in patients with pediatric onset intestinal failure (n=165). Data 
adapted from multicentre study from Italy and single centre studies from North America (Casey L 
2008, Salvia G 2008, Cowles RA 2010).  
 
 
Figure 2. Distribution of diagnoses in children with short bowel syndrome (n=141). Data adapted from 
multicentre study in Italy and single centre studies in North America (Casey L 2008, Salvia G 2008, 
Cowles RA 2010). NEC; necrotizing enterocolitis. 
 
 
 21 
Malrotation and midgut volvulus 
Malrotation of the bowel occurs after incomplete rotation and fixation of the fetal 
bowel; typically the caecum does not reach the right ileal fossa. Furthermore, fixation 
of the gut may be aberrant, small bowel may be placed on the right side and colon on 
the left with band formation between the duodenum and right colon. Malrotation often 
causes bowel obstruction, and may lead to midgut volvulus and necrosis from midgut 
to proximal colon and eventually require major bowel resection leading to IF. (Finkel 
Y 2008) 
 
 
2.1.4.2 Intestinal motility disorders 
 
Intestinal motility disorders, characterized by bowel obstruction without luminal 
occlusion, may lead to IF and long-term PN even without any bowel resection 
(Connor FL 2006). Motility disorders account for up to 10% to 25% of pediatric 
patients with IF (Guarino A 2003, Pironi L 2006, Casey L 2008, Salvia G 2008, 
Cowles RA 2010). The main intestinal motility disorders include extensive 
Hirschsprung’s disease and chronic intestinal pseudo-obstruction (CIPO). (Figure 1) 
 
Extensive Hirschsprung’s disease 
Hirschsprung’s disease is a congenital disorder affecting approximately 1 in 5000 
newborns and is characterized by an interruption of the craniocaudal migration of 
neuroblasts and absence of ganglionic innervation of the affected bowel causing 
functional obstruction (Goulet O 2006). The length of the aganglionotic segment 
varies and in 75% of patients the aganglionosis is limited to the rectosigmoid 
(Chumpitazi B 2008). Rarely the aganglionosis extends to the proximal small 
intestine (extensive Hirschsprung’s disease) leading to vomiting, bowel distension, 
malabsorption, and IF (Goulet O 2006). Extensive Hirschsprung’s disease is the 
underlying diagnosis in 5% of pediatric patients with IF (Pironi L 2006, Mazariegos 
GV 2009, Gutierrez IM 2011). Moreover, even if the small bowel of a patient with 
Hirschsprung’s disease has ganglion cells, it may have other neurologic 
abnormalities, for example involving Cajal cells with subsequent motility disorder, 
leading to IF (Vanderwinden JM 1996).  
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Chronic intestinal pseudo-obstruction (CIPO) 
CIPO refers to a heterogeneous group of rare, severe and disabling disorders 
characterized by symptoms of bowel obstruction, including radiographic signs of 
dilated bowel with air-fluid levels, without lumen occluding-lesions (Di Lorenzo C 
1999). In the United States, it is estimated that approximately 100 infants with 
congenital CIPO are born every year (Chitkara DK 2006). Symptoms associated to 
CIPO include abdominal distension (98%), vomiting (91%), constipation (77%), 
failure to thrive (62%), abdominal pain (58%), sepsis (34%), and diarrhea (31%) 
(Rudolph CD 1997). Intestinal dilatation and dysmotility incline the risk of SIBO and 
septic episodes and lead to malabsorption and malnutrition (Rudolph CD 1997). The 
diagnosis of CIPO is initially clinical, while radiographic studies are utilized to exclude 
mechanical obstruction (Chumpitazi B 2008).  
 
CIPO may be congenital or acquired, primary or secondary (Rudolph CD 1997). In 
children, pseudo-obstruction is usually primary and congenital, with a small minority 
being hereditary familial processes, and symptoms present from birth or early infancy 
(Heneyke S 1999, Lehtonen HJ 2012). Based on histopathology and pattern of 
motility abnormalities, primary and secondary forms are classified as visceral 
myopathy and visceral neuropathy (Connor FL 2006). CIPO can also be secodary to 
mitochondrial disorders, diminished intestinal cells of Cajal, inflammatory condition or 
autoimmune disease (Chitkara DK 2006). No specific therapies for CIPO are 
available and special attention is placed on nutritional support and medical 
management (Chumpitazi B 2008). In selected CIPO patients, intestinal 
transplantation may be considered as the treatment of choice (Millar AJ 2009).  
 
 
2.1.4.3 Congenital enteropathies 
 
Congenital enteropathies are extremely rare disorders, including microvillus inclusion 
disease and intestinal epithelial dysplasia (tufting enteropathy), involving the 
development of intestinal mucosa and characterized by neonatal onset severe watery 
diarrhea leading to IF (Goulet O 2006). In autoimmune enteropathy, generally 
affecting neonates and children, although cases of adult onset have been reported, 
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autoimmune-mediated damage to the intestinal mucosa leads to villous atrophy of 
the intestine, intractable diarrhea, and IF (Montalto M 2009). Immunosuppressive 
therapies have been reported to be effective in pediatric and adult patients with 
autoimmune enteropathy (Gentile NM 2012). Most patients suffering from microvillus 
inclusion disease or intestinal epithelial dysplasia remain permanently dependent on 
PN and should be considered for intestinal transplantation (Goulet O 2006).  
 
 
Table 2. Causes of intestinal failure at different ages. 
Neonatal Childhood Adult 
Short bowel syndrome Short bowel syndrome Short bowel syndrome 
Necrotizing enterocolitis Midgut volvulus Ischemia 
Gastroschisis Trauma Crohn’s disease 
Intestinal atresia Mesenteric infarction Volvulus 
Midgut volvulus Crohn’s disease Trauma 
Vascular abnormalities/thrombosis Vascular abnormalities/thrombosis Tumor 
 Tumor  
   
Motility disorders Motility disorders Motility disorders 
Aganglionosis* Aganglionosis* CIPO 
CIPO CIPO  
   
Congenital enteropathies Autoimmune enteropathy Autoimmune enteropathy 
Microvillus inclusion disease   
Intestinal epithelial dysplasia   
Autoimmune enteropathy   
Modified from Di Lorenzo C 1999, Goulet O 2004,  Casey L 2008, Salvia G 2008, and Cowles RA 
2010.  *Extensive Hirschsprung’s disease. CIPO; Chronic intestinal pseudo-obstruction.  
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2.1.5 Effects of bowel anatomy in IF 
 
In all IF patients, the overall prognosis depends on the patient age at the time of 
resection, absolute and age-adjusted length of the remaining small bowel, but also 
the remaining anatomy and function of the intestine (DiBaise JK 2004, Spencer AU 
2005, Goulet O 2006). In children with SBS, a short resection leaves more than 100-
150 cm of small intestine, large resection between 40 to 100 cm, and a massive 
resection under 40 cm (Goulet O 2006). Goulet and co-workers reported that children 
with major small bowel resection and without ileocaecal valve (ICV) are more likely to 
remain dependent on PN; 40% of these children were on PN after 8 years (Goulet O 
2005). In contrast, 80% of children with neonatal SBS and 40-80 cm of remaining 
small bowel and preserved ICV weaned off PN within one year (Goulet O 2005). In 
considering their prognosis, the age of the patients at the time of bowel resection 
should be considered as the growth potential of the bowel varies substantially 
according to patient age. For example preterm infants have great potential for bowel 
growth, as small bowel length doubles during the third trimester of gestation 
(Touloukian RJ 1983, Struijs MC 2009, Amin SC 2013). However, patients with 
intestinal motility disorder have a significant amount of intestine remaining and still 
may have severe and often irreversible IF (Di Lorenzo C 2010). Patients with 
intestinal motility disorders have demonstrated a lower probability of weaning off PN 
compared to patients with SBS (Goulet O 2006, Pakarinen MP 2009). 
 
There are three major types of remaining bowel anatomy with different outcomes in 
IF patients: 1) end-jejunostomy, 2) jejunocolic anastomosis, and 3) jejunoileocolic 
anastomosis (DiBaise JK 2004). Patients with jejunoileocolic anastomosis usually 
have the most promising overall prognosis (DiBaise JK 2004). Anatomical factors 
associated with improved survival include intact ileocaecal valve and colon, 
takedown surgery after ostomy, and primary anastomosis (Quiros-Tejeira RE 2004). 
In contrast, ileal resection is poorly tolerated because of resulting malabsorption of 
bile acids (Youssef NN 2012). Resection of the ileocaecal valve facilitates the entry 
of colonic bacteria to populate the small intestine leading to SIBO and mucosal 
inflammation, thus impairing intestinal function, prolonging PN dependence, and 
promoting bacterial translocation and sepsis  (Kaufman SS 1997, Yang H 2003, 
Goulet O 2004, Cole CR 2010). Enterectomy is associated with gastric 
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hypergastrinemia and hypersecretion (Williams NS 1985). In SBS, gastric 
hypersecretion can lead to fluid, electrolyte losses, peptic ulcers, and acidic 
environment in small bowel, resulting in bile acid precipitation with subsequent 
ineffective micelle formation, as well as inactivation of exocrine pancreatic enzymes 
(Kauffman SS 1997, Kocoshis SA 2010). Clinical features associated with different 
types of bowel resections are presented in Figure 3. 
 
 
Figure 3. Clinical features associated to diffent types of intestinal resections. GLP-2; glucagon-like 
peptide 2. 
 
 
2.1.6 Intestinal adaptation 
 
Soon after major bowel resection, intestinal adaptation in the remaining bowel yields 
an increase in fluid and nutrient absorption to the level required to maintain energy 
and fluid balance (DiBaise JK 2004, Goulet O 2004). Based on animal and adult 
studies, changes in several interrelated systems, including morphological, functional, 
biochemical, and hormonal, appear to be involved in intestinal adaptation (Jeppesen 
PB 2002, Goulet O 2004). Adaptation includes bowel dilatation, muscular 
Jejunal resection 
- Decreased absorption of energy, micronutrients, 
fluid and electrolytes 
- Decreased absorption of water-soluble vitamins 
- Promotes gastric hypersecretion 
 
Ileal resection 
-Decreased absorption of energy, micronutrients, 
fluid and electrolytes 
- Decreased absorption of bile acid  
- Decreased absorption of B12- and fat-soluble 
vitamins 
- Decreased GLP-2 and peptide YY secretion 
 
Ileocaecal valve resection 
- Promotes small intestinal bacterial overgrowth 
 
Colonic resection 
- Increased fluid, electrolyte, and fatty acid losses 
- Decreased GLP-2 and peptide YY secretion 
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hypertrophy, and mucosal hyperplasia (DiBaise JK 2004, Goulet O 2004). Mucosal 
hyperplasia is characterized by an increased number of enterocytes per unit, rate of 
enterocyte proliferation, villous height, and crypt depth (Goulet O 2004). Plasma 
citrulline, a non-essential amino acid mostly produced by enterocytes, is suggested 
as a marker of bowel function and adaptation in SBS (Bailly-Botuha C 2009, Stultz 
JS 2011).  
 
The remaining small bowel can adapt and allow partial or total weaning off PN even 
when its remaining length below the ligament of Treitz is shorter than 15 cm (Goulet 
O 2004). The presence of colon has been shown to be beneficial in SBS patients; 
colon is able to absorb water, electrolytes and fatty acids, to slow intestinal transit, 
and to stimulate intestinal adaptation (DiBaise JK 2004). Moreover, the energy 
derived from bacterial fermentation of soluble fiber and carbohydrates to short-chain 
fatty acids in colon may be substantial (Nordgaard I 1996). The complex regulation of 
intestinal mucosal growth involves hormonal mediators such as glucagon like 
peptides 1 and 2 (GLP-1 and GLP-2), neurotensin, peptide YY, growth hormone, and 
insulin-like growth factor (Baksheev L 2000, Jeppesen PB 2002, Zhang W 2008, Zhu 
W 2009). Additionally, enteral feeding stimulates the release of enterotrophic 
hormones, including gastrin, cholecystokinin, and neurotensin, and may further 
promote intestinal adaptation (Goulet O 2004). Other factors potentially affecting 
adaptation include glutamine and epidermal growth factor, and short chain fatty acids 
produced by bacterial fermentation of dietary fiber in the colon (Noorgard I 1994, 
Briet F 1995, Wilmore DW 1999, Jeppesen PB 2002, Sham J 2002).  
 
Various pharmacological agents, including growth hormone, peptide YY and GLP-2, 
have been studied to accelerate intestinal adaptation in SBS in animal models and in 
humans (Shulman DI 1992, Ulshen MH 1993, Benhamou PH 1997, Peretti N 2011, 
Jeppesen PB 2012, O’Keefe SJ 2013). In animal studies on bowel adaptation, growth 
hormone and peptide YY have shown promising results (Shulman DI 1992, Ulshen 
MH 1993, Benhamou PH 1997, Zhang W 2008, Zhu W 2009). However, in a 
prospective randomized study, growth hormone did not improve weaning off PN in 
children with SBS on long-term PN (Peretti N 2011). GLP-2 is a proglucagon-derived 
peptide produced by L-cells in the distal small bowel and colon in response to luminal 
nutrients (Goulet O 2004). In animal models, GLP-2 regulates gastric motility, gastric 
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acid secretion, intestinal hexose transport, and increases barrier function of the 
intestinal epithelium (Drucker DJ 2001, L’Heureux MC 2001). GLP-2 is shown to 
enhance the surface area of the mucosal epithelium by stimulation of the crypt cell 
proliferation, inhibition of the enterocyte apoptosis and crypt compartments (Drucker 
DJ 2001, L’Heureux MC 2001). In adult SBS patients with ileo-colic resection and 
impaired postprandial GLP-2 secretion, treatment with GLP-2 analogue, teduglutide, 
improved both weight gain and intestinal absorption of energy, and increased crypt 
depth and villus height (Jeppesen PB 2001). More recent results show that 
teduglutide is safe and reduces the number of days on PN in adult SBS patients 
(O’Keefe SJ 2013). These effects are explained by the decrease in GLP-2 levels due 
to distal small bowel and colonic resection and further reduction of adaptation 
(Scolapio JS 2001, Jeppesen PB 2002). The poor prognosis and relative lack of 
jejunal hypertrophy following ileal resection may be partly due to the resection of 
GLP-2 producing L-cells (Drucker DJ 2001, Topstad D 2001). 
 
As intestinal adaptation progresses, the amount of PN required decreases and 
eventually intestinal autonomy is achieved and PN may be discontinued. Most 
children who survive SBS achieve independence from PN within the first five years, 
althought some continue to remain PN-dependent (Spencer AU 2008, Squires RH 
2012). Children with IF may achieve intestinal autonomy even after many years on 
PN in contrast to adults who rarely wean off PN beyond two years on PN (Messing B 
1999, Squires RH 2012). Long-term nutritional status and growth must be carefully 
monitored also after weaning off PN (Leonberg BL 1998, Goulet O 2005, Mutanen A 
2013). Some children may experience malnutrition and growth failure after weaning 
off PN and require resumption of PN support, especially during puberty (Goulet O 
2005, Miyasaka EA 2010). 
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2.1.7 Nutrition in IF 
 
 
2.1.7.1 Parenteral nutrition (PN) 
 
Patients with IF may receive all or some of the required nutrients and energy 
parenterally. The amount and composition of PN solution is adjusted based on 
patient age, weight gain, height-adjusted weight, head circumference, growth, enteral 
tolerance, hydration status, and liver function (Bines JE 2009, Pakarinen MP 2009). 
Short-term PN may be administered through a peripheral vein, but for long-term PN  
a tunneled central venous catheter is required. PN is started gradually, aiming at 
calculated energy requirements with avoidance of over feeding to prevent 
hyperinsulinemia, glucose intolerance, infectious problems, and IFALD (Cavicchi M 
2000, Mirtallo J 2004). In metabolically stable patients, cyclic infusions with 
simultaneous enteral bolus feeds as tolerated are preferred to reduce risk of 
hyperinsulism and IFALD (Tillman EM 2013). Most parenteral energy is supplied as 
glucose together with an adequate amount of protein, including essential amino 
acids. Routine supplementation of fat- and water-soluble vitamins and trace elements 
as part of PN is recommended (Amin SC 2013). PN lipid emulsions, based on soy oil, 
olive oil, fish oil, or their different combinations, are rich sources of energy. Long-term 
use of PN lipids is linked to IFALD (discussed in more detail in chapter 2.2) (Carter 
BA 2007).  
 
 
2.1.7.2 Enteral nutrition 
 
Enteral nutrition is safer, cheaper, and easier to administer, but more importantly it 
has physiologic and metabolic advantages compared to PN (Bines JE 2009). 
Therefore, the management of IF includes early initiation and progressive 
advancement of enteral feeding as tolerated per orally or through percutaneous 
feeding tubes (DiBaise JK 2004, Pakarinen MP 2009). Enteral feeds should be 
tailored individually based on the remaining bowel anatomy and function (Bines JE 
2009). Nutrients requiring little or no digestion to be absorbed from the intestine, such 
as hydrolysed proteins and medium-chain fatty acids, are prefered (Bines JE 2009). 
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Breast milk nutrition is advantageous in neonates with IF (Andorsky DJ 2001). To 
control fluid and electrolyte losses through high-volume intestinal excretions enteral 
sodium supplementation, aiming at urinary sodium levels above 30 mmol/L, is used 
(Pakarinen MP 2009). Patients with colon may benefit from a diet high in complex 
carbohydrates, possibly because of short chain fatty acid production by bacterial 
fermentation (Atia A 2011). Soluble dietary fibers, such as pectin or guar gum, are 
shown to impact on colon adaptation positively and increase stool consistency in 
animal models but lack of effects in humans (Kocoshis SA 2010, Jeppesen PB 
2013). H2-receptor blockers and proton pump inhibitors are used to suppress gastric 
acid secretion in SBS patients (Amin SC 2013). Anti-diarrhea agents, including 
loperamide, codeine, ursodeoxycholic acid, and cholestyramine, may be used to 
reduce gut motility and bile acid induced diarrhea in selected SBS patients (Dicken 
BJ 2011, Amin SC 2013, Jeppesen PB 2013). 
 
 
2.1.8 Surgical treatment of IF 
 
 
2.1.8.1 Autologous intestinal reconstruction 
 
The goal of surgery is to correct the two major functional problems preventing enteral 
autonomy in IF: stasis in dilated bowel loops leading to SIBO and disordered motility 
(Jones BA 2010). The primary indication for autologous intestinal reconstructive 
surgery is to produce intestinal narrowing and lengthening in a patient who has 
reached a plateau in enteral tolerance despite maximal medical and nutritional 
management (Jones BA 2010). Many procedures aimed at enteral autonomy and 
weaning off PN have been developed, including reversed intestinal segments, 
intestinal valves, recirculating loops, longitudinal lengthening and tailoring (Bianchi), 
and serial transverse enteroplasty (STEP) (Waddell WR 1970, Persemedis D 1974, 
Bianchi A 1980, Stacchini A 1982, Panis Y 1997, Kim HB 2003). In the Bianchi 
procedure, the bowel and mesentery is divided longitudinally between mesenteric 
and antimesenteric border and finally anastomosed end to end, doubling the length 
of the bowel segment (Bianchi A 1980). The STEP procedure is based on alternative 
serial GIA-staplings on the mesenteric and antimesenteric border of the bowel 
creating a zig-zag pattern of longer and narrower bowel (Kim HB 2003). The Bianchi 
 30 
and STEP procedures have been shown to improve long-term survival and enteral 
autonomy in selected children with severe SBS (Bianchi A 1980, Kim HB 2003, 
Jones BA 2010, Pakarinen MP 2013).  
 
 
2.1.8.2 Intestinal transplantation 
 
Intestinal transplantation has become a treatment option in patients with irreversible 
IF and associated life-threatening complications (Fishbein TM 2006). Referral to 
intestinal transplant assessment and consideration for transplant listing should be 
performed in case of children with irreversible IF, persistent hyperbilirubinemia and 
liver dysfuntion, thrombosis of 2 of the 4 upper body central veins (jugular and 
subclavian), or recurrent life-threatening septic episodes (Fishbein TM 2006, Beath S 
2008, Avitzur Y 2010). Thus far, over 2000 intestinal transplantations have been 
performed worldwide; children account for more than 50% of the recipients (Avitzur Y 
2010). The 1-, 3-, and 5-year survival of transplanted children is reported up to 80-
95%, 65-84%, and 50-77%, being similar in patients with intestinal motility disorders 
and those with SBS, respectively (Avitzur Y 2010). Despite improvements in surgical 
technique, immunosuppressive medication, infection control, and understanding of 
intestinal transplant pathophysiology, the 10-year survival rate has stayed in 45 to 
50% (Avitzur Y 2010). After intestinal transplantation, 80 to 100% of patients are able 
to wean off PN with improved quality of life (Sudan D 2004, Avitzur Y 2010, Ngo KD 
2011, Pakarinen MP 2013).  
 
 
2.1.9 Complications of IF 
 
Children with IF and long-term PN are at risk for multiple potentially life-threatening 
complications such as liver disease, recurrent septic episodes, SIBO, metabolic 
derangement from gastrointestinal electrolyte losses, bone disease, and reduced 
axial growth affecting overall survival and quality of life of patients (Goulet O 2006). 
(Table 3) 
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Liver disease 
 
IFALD, a major complication of IF, is further reviewed in chapter 2.2. 
 
 
Recurrent septic episodes and loss of venous access 
 
A central venous route for long-term PN is essential in the treatment of IF (Kelly DA 
2006). Although catheter design and aseptic techniques have improved, central 
venous catheter related complications still have a significant impact on the outcome 
of IF patients (Andorsky DJ 2001, Pironi L 2003, Cober MP 2011). Squires and co-
workers showed sepsis to be the second leading cause of death and reported 8.9 
new catheter-related blood stream infections per 1000 catheter days among pediatric 
IF patients (Squires RH 2012). Poor catheter technique or insertion site and tunnel 
infections may lead to bacteremia and septicemia (Buchman AL 2003, Bines JE 
2009, Cober MP 2011). The presence of a central venous catheter can lead to 
central venous thrombosis and even embolism and further loss of venous acces and 
inability to deliver PN (Buchman AL 2003, Cober MP 2011). Furthermore, IFALD has 
been shown to be more common in children with recurrent septic episodes related to 
either central line infections or bacterial translocation from the intestine due to SIBO 
(Candusso M 2002, Heine RG 2002, Kelly DA 2010).  
 
 
Bacterial overgrowth 
 
SIBO is a frequent complication of IF, which causes nutrient malabsorption, 
deconjugation of bile acids, impaired micellar solubilization, and fat malabsorption, as 
well as increased risk for bacterial translocation and sepsis (Goulet O 2006). In 
addition, SIBO may worsen the hepatotoxity of PN and provoke the development of 
IFALD (Wolf A 1989, Braxton C 1995, Kaufman SS 1997, Sondheimer JM 1998, 
Forchelli ML 2003, Kelly DA 2006). SIBO is likely to occur in IF patients without an 
ileocaecal valve leading to the entrance of colonic bacteria to the small bowel and 
those with poor motility and dilated bowel segments (Goulet O 2006). SIBO is 
associated with vomiting, diarrhea, bowel distension, metabolic acidosis, D-lactatic 
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acidosis, and failure to thrive (Goulet O 2006). In D-lactic acidosis intestinal bacteria 
produce D-lactate, which is not metabolized and can accumulate to toxic levels 
causing increased anion gap acidosis and sometimes neurological problems ranging 
from disorientation to coma (Amin SC 2013). To treat SIBO, rotating antibiotics, 
including metronidatzole, amoxicillin, ciprofloxacin, and fluconatzole, can be used 
empirically (Pakarinen MP 2009). In selected patients, performing an intestinal 
tapering and lenghthening procedures may be mandatory to help reduce SIBO 
(Goulet O 2006).   
 
 
Impaired growth and weight gain 
 
In children suffering from chronic diseases, progressive deteriorating axial growth, 
delayed pubertal maturation, and reduced pubertal growth spurt are often noted 
(Pozo J 2002, Simon D 2002). In a cross sectional study on patients with infantile-
onset SBS at a mean age of 14.8 years, short stature and normal weight was 
reported (Olieman JF 2012). A retrospective study by Goulet and co-workers 
suggested that most neonates with SBS have normal growth pattern, experience 
normal pubertal development and achieve a normal adult height and weight (Goulet 
O 2005). As highlighted in figure 4, children with IF seem to be short and light weight 
for their age until puberty (height Z-scores from -1.4 to -0.8 in patients aged 1 to 12 
years and weight Z-scores from -1.3 to -0.5 in patients aged 1 to 16 years, P<0.05), 
but most of them undergo normal pubertal development and attain normal adult 
height (Mutanen A 2013). 
 
 
Metabolic bone disease 
 
Low bone mineral contents have been described in children with SBS during and 
after weaning off PN (Dellert SF 1998, Olieman JF 2012). A majority of patients with 
pediatric onset IF at a median age of 9.9 years were shown to have decreased bone 
mineral density (Z-score ≤-1.0 in 70% of patients) with poor vitamin D status [serum 
25-hydroxyvitamin-D (S-25-OHD) <50 nmol/l in 41% of patients] and secondary 
hyperparathyroidism (plasma parathyroid hormone >47 ng/l in 44% of patients) 
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equally during and after weaning off PN (Mutanen A 2013). Long-term PN, short 
remaining small bowel, increasing age, and insufficient calcium and vitamin D 
supplementation are risk factors for metabolic bone disease in pediatric onset IF 
(Mutanen A 2013).  
 
 
Figure 4. Height and weight (Z-scores) in intestinal failure patients from 1 to 20 years of age. The 
lines represent means and ranges. The number of patients at each measurement point is given above 
the curves. Adapted from Mutanen A et al. Horm Res Paediatr 2013;79:227-235 with permission of 
Karger.  
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Modified from Goulet O 2006, Kelly DA 2006, Duro D 2008, and Bines JE 2009. 
 
2.1.10 Patient outcomes in IF 
 
Mortality associated with pediatric IF has decreased from 40% to under 10% in 
specialized centers and likely reflects the impact of multidisciplinary intestinal 
rehabilitation programs (Andorsky DJ 2001, Schalamon J 2003, Spencer AU 2005, 
Sudan D 2005, Thompson JS 2006, Diamond IR 2007, Torres C 2007, Cole CR 
2008, Modi BP 2008, Hess RA 2011, Pakarinen MP 2013). Because mortality and 
patient outcomes are linked to the presence of liver disease, incidence of septic 
episodes, residual bowel anatomy, patient age, dependence on PN, and underlying 
disease, the reported mortality rates vary depending on the patient population 
Table 3. Complications associated to parenteral nutrition and intestinal failure. 
Liver disease 
Hyperbilirubinemia and abnormal liver enzymes 
Histological cholestasis, steatosis and fibrosis  
Cirrhosis 
Liver failure 
Cholelithiasis, biliary sludge, cholecystitis 
Hepatocellular carcinoma 
Recurrent sepsis 
Central line associated 
Bacterial translocation  
Bacterial overgrowth 
D-lactic acidosis 
Loss of venous access 
Thrombosis 
Infection 
Line dislodgement 
Dehydration and electrolyte imbalance 
Impaired growth in children 
Metabolic bone disease 
Renal dysfunction 
Hyperoxaluria 
Nephrolithiasis 
Chronic renal insufficiency 
Psychosocial 
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studied (Squires RH 2012). In adults with benign etiology of long-term home PN, the 
overall 5-year survival is estimated to be 75% depending on the underlying disease, 
age of patient, and remaining bowel anatomy (Staun M 2009). In mixed patient 
populations of children on HPN, the mean survival rate is reported to be generally 
better than in adults, with approximately 90% at 5 years (Pironi L 2012). In contrast, 
the survival rates of children listed for intestinal transplantation are as low as 35% at 
3 years (Bueno J 1999, Gupte GL 2007). In a retrospective analysis of a multicentre 
cohort of 272 pediatric IF patients the cumulative incidences for enteral autonomy, 
death, and intestinal transplantation were 44%, 26%, and 23% by 36 months 
(Squires RH 2012).  
 
Major negative prognostic factors in pediatric IF include presence of persistent liver 
disease, residual bowel length under 15 to 20 cm or under 10% of age-adjusted 
normal, presence of SIBO, prematurity and underlying disease (gastroschisis, 
mucosal inflammation) (Andorsky DJ 2001, Quiros-Tejeira RE 2004, Duro D 2008, 
Mian SI 2008, Goday PS 2009). In children with CIPO, onsets of symptoms before 
one year of age, involvement of urinary tract, midgut malrotation, or a myopathic 
histology are indicators of poor prognosis (Bond GJ 2004). IF children with residual 
bowel length over 40 cm and ileocaecal valve and/or colon preserved are more likely 
to have better outcomes (Andorsky DJ 2001, Quiros-Tejeira RE 2004, Duro D 2008, 
Mian SI 2008, Goday PS 2009).  
 
 
 36 
2.2 Intestinal failure associated liver disease (IFALD) 
 
 
2.2.1 Definition of IFALD 
 
IFALD is defined as liver disease of clinical spectrum ranging from mild cholestasis, 
steatosis and fibrosis, to liver failure with cirrhosis, portal hypertension and 
coagulopathy (Kelly DA 2006, Tillman EM 2013). Clinical diagnosis of IFALD includes 
repeatedly abnormal liver biochemistry, such as conjugated bilirubin, alanine 
aminotransferase (ALT), and glutamyl transferase (GT), while ruling out other 
potential causes of liver disease, such as medication, viral etiology, mitochondrial 
disease, thyroid disease, hemolysis, cystic fibrosis, iron storage disease, α1-
antitrypsin deficiency, and biliary tract abnormalities (Kelly DA 2010, Tillman EM 
2013). The diagnostic limits for liver biochemistry values in IFALD vary, but >1.5 
increase above the upper limit of normal for at least 2 of the 3 parameters, including 
conjugated bilirubin, ALT and GT, is widely used (Kumpf VJ 2006). Liver biopsy 
remains the gold standard for assessing histopathological changes in chronic and 
acute liver disease, including IF patients, although histopathological definitions of 
IFALD vary (Postuma R 1979, Benjamin DR 1981, Cohen C 1981 Wolfe BM 1988, 
Mullic FG 1994, Loff S 1999, Cavicchi M 2000, Peyret B 2011). 
 
 
2.2.2 Risk of IFALD and IFALD related morbidity and mortality 
 
IFALD is a major complication and the leading cause of morbidity and mortality in 
pediatric and adult IF patients (Kelly DA 2006, Carter BA 2007, Pironi L 2012, 
D’Antiga L 2013). The incidence of abnormal liver biochemistry, abnormal liver 
histology and liver failure varies between studies, probaply because of differencies in 
patient populations, underlying diseases, definition of IFALD and PNALD, duration of 
PN, and amount and composition of PN used. PNALD, defined by liver enzymes, is 
reported to occur in 15 to 60% of children and up to 85% of neonates (Kelly DA 2006, 
Pironi L 2012, Lauriti G 2014). In children with IF, the cumulative percentage of 
survival is significantly lower in patients with cholestasis compared to patients without 
cholestasis; 79% vs 95% at 1 year and 73% vs 88% at 3 years (Squires RH 2012). 
PNALD is seen more often and is associated with higher mortality in infants with 
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prematurity and low birth weight (Beath SV 1996, Christensen RD 2007, Pironi L 
2012). Among children with IFALD, end stage liver disease is reported to occur in 3% 
up to 25% (Colomb V 2007, Nasr A 2007). End stage liver disease has a mortality 
rate approaching 100% within 1 year of diagnosis if weaning off PN is not achieved 
or liver and/or intestinal transplantation is not received (Chan S 1999, Wales PW 
2005, Cowles RA 2010, Wada M 2013).  
 
 
2.2.3 Etiology and pathophysiology of IFALD 
 
The etiology of IFALD is multifactorial. In children, IFALD is related to duration, 
amount, and composition of PN, recurrent septic episodes, remaining bowel 
anatomy, SIBO, lack of enteral feeds, prematurity, and low birth weight. (Kelly DA 
2006) (Table 4) 
 
 
Duration, amount and composition of parenteral nutrition 
 
The frequency of liver dysfunction, cholestasis and liver fibrosis is shown to increase 
with duration of PN (Beale EF 1979, Kelly DA 2006, Peyret B 2011). PN lipids and 
plant sterols have been implicated in the pathogenesis of IFALD (Clayton PT 1993, 
Clayton PT 1998, Btaiche IF 2002, Carter BA 2007, Llop M 2008). A lipid dose <1 
g/kg/day is found to be beneficial in preventing IFALD (Cavicchi M 2000, Mirtallo J 
2004). Furthermore, PN fat reduction is a clinically applied approach when signs of 
IFALD occur to prevent further liver damage (Cober MP 2010, Cober MP 2012).  
 
PN lipid emulsions traditionally contain soy oil-based lipids with high concetrations of 
polyunsaturated fatty acids (PUFA), omega-6 fatty acids, and plant sterols, including 
stigmasterol, avenasterol, sitosterol and campesterol (Gabe SM 2013). Alternative 
lipid emulsions have been developed by partially or totally replacing soy oil-based 
lipid with olive oil- and/or fish oil-based emulsions. Olive oil-based lipid emulsions are 
rich in omega-6 fatty acids and oleic acid, a monounsaturated fatty acid that is less 
prone to lipid peroxidation than PUFA, and contain less plant sterols compared to soy 
oil-based lipid emulsion (Carter BA 2007, Gabe SM 2013). Fish oil-based emulsions 
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contain omega-3 fatty acids and long-chain PUFAs eicosapantaenoic acid (EPA) and 
docosahexaenoic acid (DHA) and are devoid of plant sterols (Carter BA 2007). The 
downstream products of omega-6 fatty acids are proinflammatory, including 
leukotriens, prostaglandins, and tromboxane 2 and may associate to PNALD (Gabe 
SM 2013). In contrast, EPA and DHA in fish oil are thougt to have anti-inflammatory 
and hepatoprotective potential via its production of anti-inflammatory leukotriens, 
prostaglandins, and thromboxane A3 (Gabe SM 2013).  
 
Plant sterols are likely to be significant contributors to cholestasis in IF patients on 
PN (Gabe SM 2013). The serum levels of plant sterols have been shown to markedly 
increase in adults and children on soy oil-based PN with biochemical evidence of 
IFALD (Clayton PT 1993, Clayton PT 1998, Cavicchi M 2000, Hallikainen M 2008, 
Llop M 2008). Moreover, transition from soy oil-based PN to olive oil-based PN 
containing less plant sterols have been shown to decrease elevated liver enzymes, 
where as fish oil-based emulsions have been suggested to reverse cholestasis in 
neonates (Pálová S 2008, Puder M 2009). At the molecular level, plant sterols, 
especially stigmasterol, have been shown to antagonize nuclear farnesoid receptor X 
(FXR)-mediated bile acid homeostasis in hepatocytes and associate with hepatocyte 
damage (Wang H 1999, Carter BA 2007). Despite promising results on fish-oil based 
PN, devoid of plant sterols, it is not an universal solution for IFALD and an optimal 
parenteral lipid emulsion remains yet to be found (Tillman EM 2013).  
 
Other components of PN have also been studied for significance in IFALD. Nutrient 
excess in the form of either parenteral glucose or amino acids have been associated 
with changes in liver histology and biochemistry, including elevated transaminases, 
steatosis, and cholestasis (Sheldon GF 1978, Carter BA 2007). Therefore, it is 
recommended that a balanced PN provide 70-85% of non-protein calories as 
carbohydrate and 15-30% as fat (Mirtallo J 2004). In neonates and children, 
specialized age-specific formulations of crystalline amino acids are routinely used to 
contain a balanced source of essential and nonessential amino acids (Spencer AU 
2005).  
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Recurrent septic episodes 
 
IFALD is more common in children with recurrent septic episodes, whether it is 
related to central line infections or bacterial translocation from the intestine (Braxton 
C 1995, Kaufman SS 1997, Sondheimer JM 1998, Forchelli ML 2003, Kelly DA 
2006). A higher number of septic episodes has been shown to predict elevated 
bilirubin levels and cholestasis (Beath SV 1996). Intestinal stasis induced SIBO leads 
to reduction of bile flow, production of secondary bile salts, bacterial translocation, 
and sepsis, and therefore is suggested to affect development of IFALD (Kelly DA 
2006).  
 
 
Bowel anatomy and bacterial overgrowth 
 
The absolute and percentage of age-adjusted small bowel length are predictive for 
survival, weaning off PN and cholestasis in children with IF (Spencer AU 2005). 
Peyret and co-workers reported in a retrospective study of 42 children on PN that 
histological liver fibrosis was associated with shorter length of small bowel (Peyret B 
2011). Intestinal dysmotility and lack of ICV leading to SIBO may impair intestinal 
immunity, decrease intestinal immonoglobulin A levels, enchance production of 
hepatotoxic cytokines and increase intestinal permiability (Btaiche IF 2002). IFALD is 
shown to be more common in children with recurrent septic episodes related either to 
central line infections or bacterial translocation from the intestine due to SIBO 
(Candusson M 2002, Heine RG 2002, Kelly DA 2010). Furthermore, SIBO may 
worsen the hepatotoxity of PN and provoke development of IFALD (Wolf A 1989, 
Braxton C 1995, Kaufman SS 1997, Sondheimer JM 1998, Forchelli ML 2003, Kelly 
DA 2006).  
 
 
Prematurity and low birth weight 
 
Several case series have shown that prematurity and low birth weight are significant 
risk factors for PNALD and IFALD; The lower the gestation age, the higher the 
elevation of serum bilirubin concentrations and the more rapid and severe the 
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development of liver disease and jaundice (Pereira GR 1981, Beath SV 1996, 
Spencer AU 2005, Cristensen RD 2007, Robinson DT 2008). Premature infants have 
reduced bile salt pool, uptake and synthesis of bile salts, and entero-hepatic 
circulation compared to full term babies (Watkins JB 1975, Wessel JJ 2007). 
Moreover, the liver of premature babies is more susceptible to toxic damage 
(Watkins JB 1975, Wessel JJ 2007). Due to the physiologic immaturity of the 
neonatal liver and hepatic excretory system, premature neonates are likely to be at 
great risk for IFALD with increased mortality (Kelly DA 2010).  
 
 
Lack of enteral feeding 
 
IFALD is more frequent in children who are unable to tolerate enteral feeds 
compared to those who tolerate even partial enteral nutrition (Beath SV 1996, 
Kaufman SS 2002, Kelly DA 2006). In IF, the lack of enteral feeds may lead to 
reduced gastrointestinal hormone secretion, including GLP-2, peptide YY, gastrin, 
motilin, glucose-dependent insulinotrophic polypeptide, secretin, pancreatic 
polypeptide, cholecystokinin, and vasoactive intestinal peptide, decreased bile flow, 
formation of biliary sludge, intestinal stasis and SIBO which can further promote 
IFALD (Greenberg G 1981, Shulman RJ 2000). Interestingly, the use of 
cholecystokinin-octapeptide failed to reduce the incidence of PN associated 
cholestasis in a multicenter double-blind randomized controlled trial in neonates on 
PN (Teitelbaum DH 2005). Lack of enteral nutrition and use of total PN resulted in 
loss of villous height and decline in epithelial growth in intestine in animal models 
(Shou J 1994, Niinikoski H 2004). Furthermore, use of total PN leads to loss of 
epithelial barrier function in experimental models and in humans (Buchman AL 1995, 
Peterson CA 1997, Yang H 2003). This loss of intestinal barrier function may result in 
endotoxins and even bacterial translocation to the systemic circulation (Yang H 
2009). 
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Table 4. Risk factors of intestinal failure associated liver disease. 
Long-term parenteral nutrition 
Components of parenteral nutrition  
Excess lipids (>1 g/kg/day) 
Plant sterols 
Excess dextrose 
Excess amino acids 
Toxic components of PN (+/- peroxidation) 
Lack of essential fatty acids 
Lack of essential amino acids 
Bacterial overgrowth  
Septic episodes 
Bacterial translocation 
Central line associated 
Bowel anatomy associated factors 
Short remaining small bowel 
Lack of ileocaecal valve 
Intestinal inflammation 
Prematurity and low birth weight 
Lack of enteral feeding 
Modified from Beath SV 1996,  Kelly DA 2006, Goulet O 2006, and Carter BA 2007. 
 
 
2.2.4 Clinical features of IFALD 
 
Elevated liver biochemistry values, including ALT, AST (aspartate aminotransferase), 
GT, total and conjugated bilirubin, are the earliest sings of liver dysfunction in IF 
(Btaiche IF 2002). The time to onset of liver dysfunction after starting PN is difficult to 
predict and varies with the precence or absence of different risk factors of IFALD 
(Benjamin DR 1981). In infants on soy oil-based PN serum conjugated bilirubin, 
alkaline phosphatase (ALP), and AST concentrations were elevated after 2.2 ± 0.2, 4 
± 0.8, 4.6 ± 0.7 weeks on soy oil-based PN (Postuma R 1979). As liver dysfunction 
progresses, a fall in albumin and prolonged coagulation occurs (Kelly DA 2010). With 
development of end-stage liver disease, cirrhosis, splenomegaly with 
thrombocytopenia, ascites, and varices are encountered (Kelly DA 2010). 
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2.2.5 Liver histology 
 
 
2.2.5.1 Normal liver histology  
 
Normal liver has a regular structure based on portal tracts, efferent veins, and 
hepatocytes arranged in plates and separated by a sinusoidal labyrinth. The smallest 
portal tracts contain portal venules, hepatic arterioles and interlobular bile ducts. 
Blood from both venules and arterioles passes through the sinusoidal system to the 
efferent hepatic venules, larger veins, and finally the vena cava. Bile flows from the 
smallest ducts to larger ducts and through the common bile duct to the small 
intestine. To describe the functional relationship between the various structures of 
the liver, the two most widely used models are the classic lobule and the Rappaport’s 
acinus (Figure 5). The classic lobule has an efferent venule in the centre and portal 
tracts in the periphery. The acinus is based on a terminal portal tract, with blood 
passing from this, through successive less well-oxygenated parenchymal zones 1, 2 
and 3, to efferent venules. Hepatocytes localized around the portal triad (portal vein, 
bile duct, and artery) display different metabolic activities than those lining the central 
vein; for example, cells closest to the portal triad perform most of the cholesterol 
synthesis, have the best circulation, and the most nutrients, but also suffer first from 
bile flow obstruction (Jungermann K 1996). Pericentrally localized hepatocytes 
perform glucose metabolism and are most vulnerable to ischemia (Jungermann K 
1996). (Lefkowitch JH 2010)  
 
Evaluation of liver histology is performed using several stains after the liver biopsy is 
fixed in formalin, embedded in paraffin, and sliced. Haematoxylin and eosin (H&E) 
and Periodic acid-Schiff stains (PAS) are used for screening of basic liver structure, 
fibrosis, steatosis, and inflammatory infiltrate. Reticulin stain is helpful in the accurate 
assessment of structural changes and detection of portal and lobular fibrosis. In 
cholestasis, hepatocellular swelling and pallor and accumulation of copper in affected 
cells is seen in copper staining. Ductular reaction containing proliferated ductule-like 
structures is seen in cytokeratin-7 (CK7) staining, normally not demonstrable in 
hepatocytes, in cholestatic liver. Iron stain enables iron but also bile, lipofuscin and 
other pigments to be evaluated. (Lefkowitch JH 2010) 
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Figure 5. Diagrammatic representation of a simple acinus. The acinus divided into zones 1, 2, and 3, 
with three adjacent lobules for comparison in the figure. Portal tracts (P) contain bile ducts, arterioles 
and venules. E, efferent vein (central vein or terminal hepatic venule). Adapted from Lefkowitch JH, 
eds. Liver biopsy interpretation. Volume 1. 8th ed. Philadelphia: Elsevier Saunders, 2010:18 with 
permission of Elsevier.  
 
 
2.2.5.2 Liver histology in IFALD  
 
Data available on liver histology in IFALD is limited as most studies are retrospective 
and often include patients on PN with other underlying diagnoses than IF (Table 5). 
The hepatic dysfunction associated with long-term PN differs in adults and children 
as infants have more histological cholestasis and adults have steatosis (Postuma R 
1979, Benjamin DR 1981, Wolfe BM 1988, Mullic FG 1994, Loff S 1999, Cavicchi M 
2000). Retrospective studies on children on long-term PN with mixed underlying 
diagnoses have reported liver steatosis, fibrosis, and cholestasis in up to 68%, 94%, 
and 100% of patients (Postuma R 1979, Cohen C 1981, Peyret B 2011). In autopsy 
samples of 31 children on total PN, Cohen and co-workers described the liver 
damage to progress from steatosis and portal inflammation to canalicular cholestasis 
and ductular proliferation, further to portal fibrosis, and eventually micronodular 
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cirrhosis (Cohen C 1981). Longer duration of PN is shown to relate on progression of 
histological cholestasis (Zambrano E 2004). Fibrosis associates with short remaining 
small bowel and long duration of PN in children with IF on long-term PN (Peyret B 
2011).  
 
Parenteral plant sterols are likely to contribute on IFALD, but only a limited number of 
animal and human studies linking liver histology and PN plant sterols are available. 
Loff and co-workers compared liver histology of ten infants on PN to a rabbit model of 
IF (Loff S 1999). The study revealed similar histological findings, including fibrosis 
and bile duct proliferation, in neonates and rabbits after 1 to 4 weeks on soy-based 
PN (Loff S 1999). In neonatal piglets on total PN, including amino acids, dextrose 
and soy oil-based lipids, liver steatosis and hepatocellular apoptosis was seen after 7 
PN days (Wang H 2006). Interestingly, a rabbit model comparing parenteral soy oil-, 
olive oil- and soy oil-based emulsion with added fish oil showed more fibrosis in 
rabbits receiving the latter (Kohl M 2007). In children with IF transition from soy-
based PN lipids to fish oil results in reversal of biochemical cholestasis, but 
histological fibrosis is reported to persist (Gura KM 2008, Soden JS 2010). 
 
Although serum liver enzymes usually slowly normalize after weaning off PN, the 
liver changes may persist or even progress (Rodgers BM 1976, Cohen C 1981, 
Dahms BB 1981, Moss RL 1993, Hasegava T 2002, Pichler J 2010). Dahms and co-
workers described a complete resolution of histological portal inflammation and bile 
duct proliferation, but persistent cholestasis and periportal fibrosis while serum liver 
biochemistry normalized in six neonates after weaning off PN (Dahms BB 1981). 
Moss and co-workers found progression of liver steatosis and fibrosis while weaning 
off PN (Moss RL 1993). Hasegava and co-workers reported resolution of liver 
steatosis and cholestasis but persistent fibrosis after isolated small bowel 
transplantation and weaning off PN in a child with IFALD (Hasegawa T 2002). Case 
reports of liver malignancy in patients with IFALD have been published (Vileisis RA 
1982, Yeop I 2012). However, the type and reversibility of the liver injury and the 
effect of previously described risk factors of IFALD on liver histology during and after 
weaning off PN in IF patients are still insufficiently characterized (Table 5). 
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2.2.6 Serum fibroblast growth factor 21 and liver steatosis 
 
Fibroblast growth 21 (FGF21), a hormone primarily secreted by the liver, regulates 
glucose and lipid metabolism and relates to liver steatosis in animals and humans 
(Itoh N 2004, Kharitonenkov A 2005, Kharitonenkov A 2007, Xu J 2009, Fisher FM 
2011). In experimental animal models administration of recombinant FGF21 results in 
reduced levels of blood glucose, insulin, triglycerides, low-density lipoprotein (LDL) 
cholesterol and high-density lipoprotein (HDL) cholesterol, and reversed fat 
accumulation in the liver (Kharitonenkov A 2005, Xu J 2009). In humans, increased 
serum FGF21 levels are associated with obesity, insulin resistance, impaired glucose 
tolerance, hypertriglyceridemia, and liver steatosis (Chen WW 2008, Zhang X 2008, 
Chavez AO 2009, Li H 2009, Dushay J 2010, Angelin B 2012). In adults with 
nonalcoholic fatty liver disease, serum and liver FGF21 concentrations, as well as 
hepatic expression of FGF21, are increased in parallel with liver steatosis (Chen WW 
2008, Dushay J 2010). Serum FGF21 was previously suggested as a biomarker of 
hepatic lipid accumulation in adults with type 2 diabetes mellitus and nonalcoholic 
fatty liver disease (Chen WW 2008, Dushay J 2010). The significance of serum 
FGF21 in IF and associated liver disease remains unclear.
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3 Aims of the study 
 
Various risk factors have been linked to IFALD, but the type and reversibility of 
histological liver injury and its risk factors are insufficiently characterized. In this 
thesis, studies on the incidence of long-term PN and IFALD, risk factors of IFALD, 
including parenteral plant sterols, and liver histology were performed to determine the 
long-term effects of pediatric onset IF on liver function and histology.  
 
The specific aims were: 
 
1) To investigate interrelations between serum non-cholesterol sterols, including 
plant sterols and cholesterol precursors, PN, liver function and liver histology in 
pediatric onset IF 
 
2) To study the incidence of long-term PN, associated liver disease, and other 
associated complications in neonates and children in Finland 
 
3) To characterize the risk factors of IFALD and long-term changes in liver 
histopathology and evaluate the effects of risk factors of IFALD on liver histology 
during and after weaning off PN in pediatric onset IF  
 
4) To assess serum FGF21 levels in relation to liver steatosis, serum lipids, and 
glucose homeostasis in pediatric onset IF 
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4 Patients and methods 
 
 
4.1 Patients (I-IV) 
 
Study I 
In study I, all patients with pediatric onset IF stabilized on long-term PN treated in 
Children’s Hospital, Helsinki University Central Hospital, in 2010 were invited to 
participate in the follow-up study. Eleven patients (100%) at mean age 6.3 years 
(range 1.6-16) were recruited. (Table 6) 
 
Study II 
In study II, all pediatric patients (age <17 years) receiving long-term PN (>28 days), 
including daily infusions of carbohydrates and protein with or without lipids, treated in 
Finland’s five University Hospitals (Helsinki, Tampere, Turku, Kuopio and Oulu) 
between November 2009 and November 2010 were prospectively identified and 
recruited in the study. Patients with a malignant primary disease were excluded. The 
pediatric units of the five University Hospitals treat all prematurely born newborns 
and pediatric patients on prolonged PN in Finland allowing all-inclusive nationwide 
patient identification. Altogether 39 patients on long-term PN, including 28 neonates 
and 11 children, were recruited. At inclusion, the mean ages of neonates and older 
children were 50 days (range 20-126) and 6.9 years (2.1-16.6). (Table 6) 
 
Studies III and IV 
For studies III and IV, the medical records of patients with pediatric onset IF treated 
in Children’s Hospital, Helsinki University Central Hospital, from January 1984 to 
August 2010 were reviewed. A total of 56 patients were identified, and 52 of them 
were alive. Eligible patients were invited to participate in the cross-sectional study. Of 
the eligible patients, 38 patients (73%) at median age of 7.2 years (range 0.2-27) 
participated in study III, of which 35 (67%) patients also participated in study IV. 
(Table 6) 
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4.2 Controls (I-IV) 
 
In study I, II, and IV, healthy day-case surgery patients (i.e. inguinal hernia, umbilical 
hernia, undescended testes) matched for age and sex without evidence of intestinal 
disease, diabetes, or dyslipidemia served as controls for serum non-cholesterol 
sterols and serum FGF21 measurements. In study II, neonates on long-term PN 
were compared to healthy controls as well as older children on PN. In study III, the 
liver histology of IF patient was compared to liver biopsies of age-matched liver 
transplant donors. (Table 6) 
 
 
4.3 Methods (I-V) 
 
 
Study design and data collection (I-IV) 
 
Collection of clinical data included underlying diagnoses, gestational age, birth weight 
and height, surgical procedures and complications, patient outcome, and anatomy of 
the remaining bowel. Anatomy of the remaining bowel, including length of small 
bowel, ileum, and colon and presence of ileocaecal valve, was obtained from the 
original operative records. Age-adjusted bowel length was calculated based on 
published age-specific normal values (Struijs MC 2009). IF was defined as over 50% 
resection of small bowel or duration of PN over 30 days. (I-IV) 
 
Study I 
During the follow-up (median 207 days, range 97-646), the PN regimen was kept 
virtually unchanged. Repeated measurement of serum plant sterols, cholesterol 
precursors and liver biochemistry were performed a median 4 times (range 2-6) 
prospectively, approximately every other month (range 2 weeks-6 months). At the 
time of each measurement, the exact composition and amount of PN was recorded 
between the test points. Liver biopsy was obtained in eight patients. Parenteral and 
enteral cholesterol and plant sterol intake was calculated based on parenteral and 
enteral emulsions analyzed for plant sterols, squalene, and cholesterol similar to 
serum non-cholesterol sterols as described below (see page 51). (Table 6) 
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Study II 
In study II, the patients were followed for one year, including the time of inclusion, 2 
and 4 weeks after newly started PN, and there after every 12 weeks during PN for 
one year. If a patient weaned off PN during the follow-up, the last follow-up point was 
one month after discontinuation of PN. In every follow-up point, blood samples were 
collected, the exact composition and amount of PN, medications, antibiotic therapy 
as intravenous antibiotic days, growth, septic episodes, were prospectively collected. 
Antimicrobial therapy was recorded as intravenous antibiotic days, including 
intravenous antibiotic use one month before inclusion in children and between birth 
and inclusion in neonates. (Table 6) 
 
Studies III and IV 
In cross sectional studies III and IV, the duration of PN, composition of PN during 
three months preceding liver biopsy, number of blood culture positive septic episodes 
from birth to study date, and surgical procedures, were collected from patient 
records. The cross-sectional studies included clinical examination, blood samples, 
abdominal ultrasound, gastroscopy, and liver biopsy. (Table 6) 
 
 
Clinical examination (III, IV) 
 
Clinical examination, including weight, height and blood pressure measurements, 
and evaluation of pubertal development according to Tanner staging (Tanner J 
1962), was done by the primary researcher. Body mass index (BMI) was calculated 
as [weight (kg)/ height (m2)] for adults. In children, body mass index-for-age (ISO-
BMI) was calculated (over two year-olds) and height and weight were expressed as 
Z-scores according to Finnish reference values (Saari A 2011).  
 
 
Gastroscopy (III) 
 
Gastroscopy, performed for evaluation of possible esophageal varices, was done 
during the same general anesthesia as the liver biopsies by an experienced 
endoscopist.  
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Abdominal ultrasound (III) 
 
Abdominal ultrasound was performed by a pediatric radiologist to evaluate the overall 
appearance of liver, biliary tract pathology, portal venous flow, and spleen size.  
 
 
Blood samples (I-IV)  
 
All blood samples were drawn after overnight fast. In studies I and II, repeated 
measurements of serum fat-soluble vitamins, liver biochemistry, serum cholesterol 
and non-cholesterol sterols, including plant sterols, cholestanol and cholesterol 
precursor sterols, and squalene were done. In studies III and IV the blood samples 
were collected the day before liver biopsy. The biochemical parameters used in 
studies I-IV are shown in Table 7. 
 
Serum cholesterol and non-cholesterol sterols (I, II, IV) 
Serum cholesterol and non-cholesterol sterols, including cholestanol, plant sterols 
(stigmasterol, avenasterol, sitosterol,  campesterol), and cholesterol precursor sterols 
(cholestenol, lathosterol, desmosterol), and squalene, were measured from 
nonsaponifable material by gas-liquid chromatography, on a 50-m-long SE-30 non-
polar capillary column (Ultra 1 Column, Agilent Technologies, Palo Alto, CA), with 5α-
cholestane as the internal standard (Miettinen TA 1983, Miettinen TA 1988). Non-
cholesterol sterols and squalene in the serum were expressed as ratios to the 
cholesterol concentration of the same gas-liquid chromatography run, that is, 100 x 
µg/mg of cholesterol, to exclude the effects of varying serum lipoprotein 
concentration. (I, II) 
 
Serum cholesterol and triglyceride levels, and that of HLD-cholesterol, after 
precipitation of apolipoprotein-B containing lipoproteins, were determined by 
commercial kits (Boehring Diagnostica, Mannheim, Germany and Wako Chemicals, 
Neuss, Germany). LDL-cholesterol was calculated according to Friedewald and co-
workers (Friedewald WT 1972). (I, II, IV) 
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Serum FGF21 (IV) 
The serum samples for FGF21 were prepared by centrifugation after blood collection 
and stored at -20˚C until analyzed. FGF21 concentrations were measured by ELISA 
kit (BioVendor, GmbH, Heidelberg, Germany) according to the manufacturer’s 
instructions. Intraassay coefficient of variation was 3% and interassay coefficient of 
variation 12.6%. In statistical analyses, the values below the sensitivity of the assay 
were assigned at value 7 pg/mL, and both actual and log-transformed values were 
used.  
 
Plasma amino acids (IV) 
To determine plasma citrulline concentration, plasma amino acids were measured by 
using automatic amino acid analyzer (Biocrom 30 Physiological and Midas 
Autosampler, Biochrom Limited, Cambridge, England). Amino acids, separated by 
cation-exchange liquid chromatography, were detected spectrophotometrically after 
reaction with ninhydrin reagent.  
 
Liver biochemistry and other laboratory measures (I-IV) 
Serum or plasma ALT, GT, AST, bilirubin, conjugated bilirubin, bile acids, albumin, 
prealbumin, vitamins A, E and S-25-OHD, platelets and coagulation markers 
(tromboplastin time; TT, international normalized ratio; INR, activated partial 
tromboplastin time; APTT), glucose, glycosylated hemoglobin (HbA1c), insulin, leptin 
and creatinine were measured by routine hospital methods. In study IV, insulin 
resistance was evaluated with homeostasis model assessment (HOMA-IR) 
(Matthews DR 1985). The cut-off for the diagnosis of insulin resistance was set at 
>2.5 (Tresaco B 2005). 
 
HOMA-IR= Fasting glucose (mmol/L) / Fasting insulin (mU/L) 
  22.5 
 
For studies III and IV, AST-to-platelet ratio index (APRI) was calculated according to 
Wai and co-workers (Wai CT 2003).  
 
APRI= AST level / Upper limit of normal AST  x 100 
 Platelet count (109/L) 
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Table 6. Aims, study type and design, patients, controls and data collection in studies I-IV. 
 Study I Study II Study III Study IV 
     
Aim of the study To study 
interrelations 
between serum 
non-cholesterol 
sterols, liver 
function and 
histology, and 
characteristics of 
PN in pediatric 
onset IF 
- To evaluate 
incidence of long-
term PN and 
associated 
complications  
- To describe 
significance of PN 
plant sterols on 
neonatal IFALD 
 
To characterize 
liver histology and 
evaluate risk 
factors of IFALD 
in pediatric onset 
IF 
To evaluate 
serum FGF21 
levels in relation 
to liver steatosis, 
serum lipids, 
glucose 
homeostasis and 
renal function in 
pediatric onset IF 
     
Study type Prospective 
follow-up  
Prospective 
follow-up  
Cross-sectional Cross-sectional 
 Median 209 days 1 year   
     
Study design - Repeated 
laboratory tests* 
- Liver biopsy  
- Prospective 
collection of 
clinical data 
- Repeated 
laboratory tests*  
- Prospective 
collection of 
clinical data 
- Laboratory 
tests* 
- Abdominal 
ultrasound 
- Gastroscopy  
- Liver biopsy 
- Collection of 
clinical data  
- Laboratory 
tests*  
- Liver biopsy 
- Collection of 
clinical data  
     
Patients (n) 11 28 neonates  
11 children 
38 35 
     
Inclusion criteria Children with IF 
on long-term PN 
treated in 
Children’s 
Hospital, Helsinki 
University Central 
Hospital 
Children on PN 
over 28 days 
without malignant 
primary disease 
treated in Finland  
 
IF patients born 
between 1984-
2010 and treated 
in Children’s 
Hospital, Helsinki 
University Central 
Hospital 
IF patients born 
between 1984-
2010 and treated 
in Children’s 
Hospital, Helsinki 
University Central 
Hospital 
     
Liver histology (n) 8 0 38 30 
     
Controls (n) 20 32 15 59 
     
Inclusion criteria Healthy age and 
sex matched day-
case surgery 
patients served as 
controls for serum 
cholesterol and 
non-cholesterol 
sterols  
 
- Healthy age and 
sex matched day-
case surgery 
patients served as 
controls for serum 
cholesterol and 
non-cholesterol 
sterols  
- Neonates on 
long-term PN 
were compared to 
older children on 
long-term PN 
Liver biopsies of 
age-matched liver 
transplant donors 
seved as controls 
for liver histology 
Healthy age and 
sex matched day-
case surgery 
patients served as 
controls for serum 
FGF21 
IF; intestinal failure, IFALD; intestinal failure associated liver disease, PN; parenteral nutrition, FGF21; 
fibroblast growth factor 21. * See Table 7 for laboratory tests. 
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Table 7. Biochemical parameters used in the thesis. 
Parameter Units Study 
  I II III IV 
Serum lipids      
Total cholesterol mmol/L x x  x 
High-density lipoprotein cholesterol (HDL) mmol/L x x  x 
Low-density lipoprotein cholesterol (LDL) mmol/L x x  x 
Triglycerides  mmol/L x x  x 
Non-cholesterol sterols and squalene 100x µg/mg of cholesterol 
and µmol/L 
x x   
Liver biochemistry      
Plasma alanine aminotransferase (ALT) U/L x x x x 
Plasma aspartate aminotransferase (AST) U/L x x x x 
Plasma glutamyl transferase (GT) U/L x x x x 
Plasma bilirubin µmol/L x x x x 
Plasma conjugated bilirubin  µmol/L x x x x 
Serum bile acids µmol/L  x   
Plasma albumin g/L x  x x 
Plasma prealbumin mg/L x  x x 
Plasma tromboplastin time (P-TT) % x x x x 
Plasma activated partial tromboplastin time (P-APTT) s   x  
International normalized ratio (INR)    x x 
Blood platelets E9/L   x x 
Fat soluble vitamins      
Serum Vitamin A µmol/L x x   
Serum Vitamin E µmol/L x x   
Serum Vitamin D (25-hydroxy-D vitamin) nmol/L x x   
Glucose homeostasis      
Plasma glucose  mmol/L    x 
Plasma glycosylated hemoglobin (HbA1c) mmol/mol    x 
Serum insulin mU/L    x 
Serum leptin  µg/L    x 
Plasma creatinine µmol/L    x 
Plasma citrulline  µmol/L    x 
Serum Fibroblast growth factor 21 (FGF21) pg/mL    x 
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Liver biopsies and histological analyses (I, III, IV) 
 
In study I, liver histology was analyzed based on the original pathology report. Liver 
fibrosis was scaled from 0 to 3 (0=no fibrosis, 1=fibrosis, 2=portal-portal bridging 
fibrosis, 3=cirrhosis). Cholestasis, steatosis and inflammation were recorded as 
absent (=0), mild (=1), moderate (=2) or severe (=3). 
 
For studies III and IV, ultrasound-guided core needle liver biopsies were taken under 
general anesthesia. Experienced pediatric radiologists performed the core needle 
liver biopsies, after which patients were followed over night at hospital. After liver 
biopsy, one complication occurred: a small right-sided pneumo-thorax, which 
resolved spontaneously. The control liver biopsies were wedge biopsies of age-
matched liver transplant donors (III). The biopsies were fixed in formalin, embedded 
in paraffin, sliced, and stained with H&E. Additional stainings included reticulin, PAS, 
copper, and iron (Scheuer PJ 2006). Immunostaining for CK-7 was performed using 
SP52 monoclonal antibody and Ultra View Universal Detector Kit (Vienna, Tuscon, 
Arizona). Two experienced pediatric liver pathologists and the primary researcher, 
blinded to clinical data, reviewed the slides together until consensus was reached. 
The number of portal tracts and overall liver structure were evaluated to determine 
the adequacy of the biopsy specimen. The liver biopsies were evaluated for fibrosis 
[lobular, portal, Metavir staging (Bedossa P 1996), Ishak staging (Ishak K 1995)], 
steatosis, cholestasis, bile ductular proliferation, and portal inflammation as outlined 
in Table 8. Steatosis was classified as micro- and macrovesicular. Presence of 
hepatocyte apoptosis, foamy degeneration, Mallory bodies, pseudo-rosettes, and 
extramedullar hematopoiesis was recorded. For analytical purposes, cholestasis was 
defined as the highest of the three cholestasis grades. When portal inflammation was 
present, the distribution of inflammatory cells was recorded. (Cohen C 1981, Scheuer 
PJ 2006, Peyret B 2011) 
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Table 8. Grading and staging of histological findings in the liver biopsies used in studies III and IV. 
Histological finding Scale Definition 
Fibrosis    
Lobular 0 Absent 
 1 Present 
 2 Prominent 
Portal 0 Absent 
 1 Fibrous expansions of most portal areas 
 2 Focal portal-to-portal bridging 
 3 Marked bridging 
 4 Cirrhosis 
Metavir (Bedossa P 1996) 0 No fibrosis 
 1 Portal fibrosis without septa 
 2 Portal-portal fibrous septa 
 3 Portal-portal and portal-central fibrous septa 
 4 Cirrhosis 
Ishak (Ishak K 1995) 0 No fibrosis 
 1 Fibrous expansions of some portal areas, with or 
without short fibrous septa 
 2 Fibrous expansions of most portal areas, with or 
without short fibrous septa 
 3 Fibrous expansions of most portal areas with 
occasional portal-portal bridging 
 4 Fibrous expansions of portal areas with marked 
bridging portal-portal as well as portal-central 
 5 Marked bridging (portal-portal and/or portal-
central) with occasional nodules 
 6 Cirrhosis 
Steatosis   
Proportion of hepatocytes affected 0 Absent 
 1 <25% of hepatocytes 
 2 25-50% of hepatocytes 
 3 >50% of hepatocytes 
Foamy degeneration 0 Absent 
 1 <25% of hepatocytes 
 2 25-50% of hepatocytes 
 3 >50% of hepatocytes 
Cholestasis   
Intracellular, canalicular and ductular 0 Absent 
 1 Minimal 
 2 Marked 
 3 Prominent 
Ductular proliferation 0 Absent 
 1 Focal 
 2 Generalized 
CK7 expression in periportal hepatocytes 0 Absent  
 1 Rare 
 2 Present 
 3 Prominent 
 4 Extensive 
CK7 positive ductular reaction 0 Absent  
 1 Present 
 2 Prominent 
Portal inflammation 0 Absent 
 1 Rare 
 2 Present 
 3 Prominent 
 4 Extensive 
Accumulation of copper or iron 0-4 Absent-Extensive 
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4.4 Statistical analyses (I-IV) 
 
Descriptive statistics were expressed as median or mean and range or as 
frequencies and percentages. The Kolmogorov-Smirnov test and graphics were used 
to assess distributions. In cases of non-normal distributions, non-parametric tests 
were chosen. Differences between two groups were tested for significance using 
Mann-Whitney U-test (I, II, IV) and independent samples T-test (III), as appropriate. 
Analysis of variance (one-way ANOVA) was applied to compare more than two 
groups (IV). Categorical variables were tested with Fisher exact test (III, IV). 
Correlations were tested by Spearman rank correlation test (I-IV). Multivariate 
stepwise regression and multivariate logistic regression analyses were done to 
identify predictors of liver fibrosis in study III. In study IV, a multiple stepwise 
regression model was performed to identify predictors of serum FGF21 level. All tests 
were two-tailed and the level of statistical significance was set at 0.05 (I-IV).   
 
 
4.5 Ethical considerations (I-IV) 
 
The study protocols conform to the ethical guidelines of the 1975 Declaration of 
Helsinki and were approved by the ethics committee for Pediatric, Adolescent 
Medicine and Psychiatry in the Hospital District of Helsinki and Uusimaa (I-IV) and by 
the ethical committees of Tampere, Turku, Kuopio, and Oulu University Hospitals (II). 
The participants and their parents were fully informed about the study protocol, 
collection of data and the use of collected data. All patients participated in the studies 
on a voluntary basis. An informed written consent was received from all patients, 
controls, and/or their parents. All liver biopsies and gastroscopies of patients were 
performed during general anesthesia. The participants were informed about the study 
findings, and, if needed, appropriate care was arranged. 
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5 Results 
 
 
5.1 Incidence of long-term PN and IFALD in neonates and children (II, III) 
 
In study II, of all neonates born in Finland during the one year follow-up period, 
0.05% (28:60 430, 46:100 000 live births) required long-term PN. Neonates born 
before 37 weeks of gestation treated in neonatal intensive care units needed long-
term PN more often (2.0%, 24/1223) compared to all children born in Finland during 
the follow-up. (II) 
 
IFALD, defined by liver biochemistry, occured in 27% of older children and in 63% of 
neonates on long-term PN (II). The overall survival was 89% among neonates on 
long-term PN as three neonates died due to septic complications (II). In study III, of 
the 56 identified IF patients, four had died (7%), including end-stage liver disease in 
two and septic complications in two as a cause of death, and one patient had 
esophageal varices and portal hypertension as a sign of end-stage liver disease. 
 
 
5.2 Septic episodes (II, III) 
 
During PN, blood culture positive septic episodes were more frequent among 
neonates (1.6 septic episodes per patient) than in children (1.0 septic episodes per 
patient) (P<0.05) (II). Staphylococcus epidermidis (56% of blood cultures in 
neonates, 33% of blood cultures in children) was found to be the most prevalent 
pathogen. Other pathogens found in blood cultures are shown in table 9 (Mutanen A 
et al, unpublished results). The absolute number of septic episodes and per 1000 
catheter days was equal in patients on PN [mean 2.7 septic episodes (range 0-10) 
and mean 3.6 septic episodes per 1000 catheter days (range 0-20)] and patients 
weaned off PN [1.2 (0-7) and 2.9 (0-28)] (III).  
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Table 9. Septic episodes and intravenous antibiotic treatment in neonates and children with IF. 
Variable Neonates  Children P-value° 
Number of patients 21 11  
Number of septic episodes per patient 1.6 1.0 <0.05 
Number of patients    
with septic episode 11 (53) 2 (18) 0.066 
One septic episode 6 (29) 2 (18) 0.526 
≥2 septic episodes  5 (24) 0 (0) 0.083 
Antibiotic days before inclusion; median (range)† 30 (7-97) 0 (0-15) <0.001 
Antibiotic days during follow-up; median (range) 5 (0-64) 0 (0-120) 0.367 
Microbes (n)    
Staphyolcoccus epidermidis  10 1  
Pseudomonas aeruginosa  3   
Enterococcus faecalis  2   
Stafylococcus, coagulase negative  2   
Acinetobacter baumannii  1   
Staphylococcus aureus* 1 1  
Escherichia coli ** 1   
Micrococcus species***  1  
Bifidobacter breve***  1  
Rhotorula glutinis (fungus)***  1  
Unpublished results from study II (Mutanen et al.). Data are number of cases (percentage). Blood 
culture results were available in 21 neonates and 11 children. †One month before inclusion in children 
and between birth and inclusion in neonates. In same blood culture *with Pseudomonas aeruginosa, ** 
with Acinetobacter baumannii. ***All tree in same blood culture. °Mann-Whitney U-test for comparison 
between neonates and children. 
 
 
5.3 Nutrition (I-IV) 
 
In studies I-IV, the daily parenteral calorie requirements were assessed individually 
based on weight gain, height-adjusted weight, head circumference, and growth. The 
patients received PN lipids mainly as an olive oil-based regimen combined with fish 
oil-based regimen in some. The patients received 2 to 7 cyclic PN infusions per week 
and were given median of 25 to 69 percent of total energy parenterally. Supplemental 
fat- and water-soluble vitamins and trace elements were routinely given as part of 
PN. The amount of parenteral fat was kept below 35% of parenteral energy needs. 
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Due to the limited maximum volume of daily infusions in neonates they often received 
a higher amount of total parenteral calories as fat compared to older children. Enteral 
nutrition was tailored individually based on bowel anatomy and function and was 
started as early as tolerated while the percentage of parenteral calories was 
gradually decreased. Enteral nutrient formulas, including primarly hydrolyzed proteins 
with medium and/or long-chain fatty acids, were used as appropriate. In neonates 
breast milk was prefered. (Table 10) 
 
 
Table 10. Composition of parenteral nutrition in patients on parenteral nutrition (PN) in studies I-IV. 
 Study     
 I II (neonates) II (children) III IV 
Patients on PN (n, %) 11 (100) 28 (100) 11 (100) 16 (42) 10 (29) 
Duration of PN (mo) 33 (18-196) 1.6 (1.0-10) 56 (4.9-212) 44 (2.5-204) 53 (2.8-170) 
PN infusions per week (n) 7 (2-7) 7 (7) 7 (2-7) 7 (2-7) 6 (2-7) 
PN energy (%)* 48 (8-100) 69 (30-100) 25 (5-100) 50 (6-100) 42 (7-100) 
PN glucose (%)** 69 (29-83) 66 (36-77) 76 (50-91) 77 (53-92) 77 (60-90) 
PN fat (%)** 29 (3-35) 24 (0-56) 19 (0-34) 13 (0-33) 13 (0-30) 
PN lipid emulsion      
Olive oil-based (n) 10 27 10 14 9 
g/kg/day 0.9 (0-2.2) 1.6 (0-2.5) 0.6 (0-1.9) 0.5 (0-1.6) 0.3 (0-0.9) 
Fish oil-based (n) 1 4 0 4 1 
g/kg/day 0.2  1.0 (0-1.5) 0 0.9 (0-1.9) 0.8 
Soy oil-based (n) 0 0 1 0 0 
g/kg/day 0 0 1.5 0 0 
Data are median (range) or frequencies (percentage).*Percentage of parenteral calories of total daily 
calorie intake. ** Percentage of glucose and fat energy of total parenteral calories.  
 
 
5.4 Liver biochemistry (I-IV) 
 
Neonates on PN had significantly higher serum GT, conjugated bilirubin, and bile 
acids compared to older children on PN (II). IFALD, defined by liver biochemistry, 
occurred more often in neonates (63%, 12/19) than in children (27%, 3/11, P<0.05) 
on long-term PN (II). During PN, serum markers of liver function were unrelated to 
the amount of PN fat, carbohydrates, and protein in children with IF (I). 
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One month after weaning off PN, the liver biochemistry tended to normalize, but 25% 
of neonates still fulfilled the criteria of IFALD (II). In study III, only 18% of children 
with IF weaned off PN showed abnormal liver biochemistry, including ALT, AST, GT, 
or conjugated bilirubin, or low plasma albumin, prealbumin or platelets, while 63% of 
those on PN had abnormal liver biochemistry (P<0.05). APRI values were 
comparable between IF patients on PN and weaned off PN (III).  
 
 
5.5 Serum fat-soluble vitamins (I, II), glucose homeostasis (IV) and renal 
function (IV)  
 
In neonates and children on long-term PN, the serum levels of vitamin E and vitamin 
D were within normal range (II). Serum vitamin A level was close to normal in 
neonates and in normal range in children during PN (I, II). Overall, glucose tolerance 
and insulin sensitivity was normal in most of the IF patients, as only one patient with 
liver steatosis had high fasting plasma glucose and HbA1c and two patients with liver 
steatosis had HOMA-IR >2.5 (IV). Renal function, measured by serum creatinine 
[median 37 (range 17-82)], was in normal age-specific range in all patients (IV). 
 
 
5.6 Serum lipids, lipoprotein and cholesterol (I) 
 
Children with IF on PN had low serum concentration of total cholesterol [median 2.75 
mmol/L (range 1.70-3.95) vs. 3.66 (2.30-4.60)], LDL cholesterol [1.40 mmol/L (0.47-
2.50) vs. 2.20 (1.10-2.60)] and HDL cholesterol [0.80 mmol/L (0.52-1.48) vs. 1.27 
(0.99-1.96)] compared to age- and sex matched healthy controls, most likely 
reflecting cholesterol malabsorption in IF patients (P<0.005 for all). The serum 
concentration of triglycerides was comparable between IF patients and controls 
[median 1.15 mmol/L (range 0.52-2.55) vs. 1.24 (0.45-5.94), P=0.906].  
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5.7 Serum non-cholesterol sterols (I, II) 
 
Serum cholesterol precursors during PN (I, II)  
During PN, serum cholesterol precursors proportions to cholesterol, including 
cholestenol (median 45.0 100x µg/mg of cholesterol vs 13.5, P<0.001), lathosterol 
(261 vs 71.0, P<0.001), and desmosterol (116 vs 86.0, P<0.001) were increased up 
to 3-fold among children with IF compared to healthy controls (I). In neonates on 
long-term PN, lathosterol proportion to cholesterol was increased compared to 
healthy controls, but lower than in older children on PN (P<0.005 for all) (II). In 
children on PN, serum cholesterol precursors, including cholestenol and lathosterol, 
were negatively related to individual and total serum plant sterol levels (P<0.05 for 
all) (I). These findings of increased cholesterol precursor levels in neonates and 
children with IF on long-term PN presumably reflect increased cholesterol synthesis 
due to malabsorption of cholesterol and bile acids. 
 
Serum plants sterols and cholestanol during PN (I, II) 
During PN, the median serum cholestanol and plant sterol levels, including 
stigmasterol, avenasterol, sitosterol, and total plant sterols, were significantly 
increased in neonates by 2- to 22-fold and in children by 2- to 11-fold compared to 
healthy age- and sex-matched controls (P<0.005) (I, II). Campesterol was increased 
among neonates on PN, but not in children on PN, compared to healthy controls (I, 
II). Total and individual serum plant sterol ratios to cholesterol were related to 
percentage of parenteral energy of total daily calories (P<0.05 for all), but not to 
absolute amounts of parenteral lipids, total or individual plant sterols, carbohydrate or 
protein (I, II). The total duration of PN reflected serum ratios of cholestanol, 
stigmasterol, avenasterol, sitosterol, and total plant sterol levels in neonates (P<0.05 
for all) (II), but not in children (I).  
 
In neonates with IFALD, the serum stigmasterol, avenasterol, total plant sterol, and 
sitosterol and cholestanol proportions to cholesterol were increased up to 3.0-, 1.8-, 
1.7-, 1.7-, and 1.7-fold compared to neonates without IFALD (P<0.05 for all) (II). Liver 
biochemistry, including ALT (r=0.557, P<0.05), AST (r=0.483, P<0.05), correlated 
with the total duration of PN (II). Furthermore, serum ratios of cholestanol, 
stigmasterol, avenasterol, and sitosterol  positively associated with serum AST, ALT, 
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and conjugated bilirubin (P<0.05) (II). Serum total plant sterol to cholesterol 
proportion associated with serum ALT (r=0.540, P<0.05) and conjugated bilirubin 
(r=0.548, P<0.05) levels (II). Serum total plant sterol/PN total plant sterol-ratio 
correlated with serum ALT and bile acids (I).  
 
Relation of liver histology, liver biochemistry, serum plant sterols and cholestanol 
during PN (I) 
In study I, some degree of liver fibrosis was found in 63% (5/8) of IF patients during 
PN. Patients with liver fibrosis, the median serum sitosterol, campesterol, 
avenasterol, stigmasterol, total plant sterol, and cholestanol concentrations were 1.1 
to 2.5 times higher compared to patients without histological liver fibrosis. However, 
the difference of serum plant sterol levels between patients with and without fibrosis 
was not statistically significant likely due to small number of patients. The serum 
concentration of total and individual plant sterols tended to correlate with the degree 
of liver fibrosis (r=0.55-0.60, P=0.16-0.12). The degree of liver fibrosis was not 
related to liver biochemistry, serum total plant sterols/PN total plant sterol-ratio, or 
amount of parenteral lipids, plant sterols, or energy. 
 
Relation of bowel anatomy, liver biochemistry, and serum plant sterols and 
cholestanol during PN (II) 
In neonates with IF on PN, the remaining age-adjusted small bowel length associated 
with the serum cholestanol to cholesterol proportion (r=-0.555, P<0.05) and bile acids 
levels (r=-0.604, P<0.05). Moreover, neonates on PN without an ICV (n=4) had a 
higher serum cholestanol proportion to cholesterol (median 607 100x µg/mg of 
cholesterol) than those patients with an ICV (n=14, median 406 100x µg/mg of 
cholesterol, P<0.01). A negative association was found between the remaining age-
adjusted colon length and the highest serum ALT, stigmasterol, avenasterol, 
sitosterol, and total plant sterol levels (r=-0.539- -0.476, P<0.05).  
 
Serum plant sterol and cholestanol after weaning off PN (II) 
One month after weaning off PN, serum cholestanol and plant sterols, including total 
plant sterols, stigmasterol, avenasterol, sitosterol, remained high in neonates 
compared to healthy controls (P<0.05 for all). In neonates weaned off PN with 
persistent IFALD serum cholestanol and stigmasterol proportions to cholesterol were 
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4.2 and 2.2-fold with simultaneously increased conjugated bilirubin and ALT levels 
compared to neonates weaned off PN without IFALD (P<0.05 for all).  
 
 
5.8 Abdominal ultrasound and gastroscopy (III) 
 
In abdominal ultrasound (n=34), abnormal appearance of the liver was seen in 4 
patients, including nodularity and increased hepatic echogenity. All patients with 
abnormal hepatic ultrasound had fibrosis (Metavir stage mean 1.5, range 1-2) and 
two had steatosis (grade 1 and 3) in liver biopsy. Excluding gallstones in one patient, 
no other biliary tract abnormalities were observed. Two patients had undergone 
cholecystectomy previously. In one patient weaned off PN, splenomegaly with 
esophageal varices (grade 2) in gastroscopy and Metavir stage 2 fibrosis in liver 
biopsy were found. Esophageal varices were not found in any other patient and all 
had normal liver vasculature.  
 
 
5.9 Liver histology in IF (I, III, IV)  
 
In study I on eleven IF patients on PN, most of the liver biopsy samples (66%, 5/8) 
showed some degree of fibrosis. Other findings were cholestasis (n=3), steatosis 
(n=1), reactive changes (n=1), and inflammation (n=2). 
  
In study III, liver histology was abnormal in most of the IF patients (84%). Abnormal 
liver histology was equally common during PN (in 94%) and after weaning off PN (in 
77%) (P=0.370). In IF patients, the frequency of liver fibrosis (in 74% of IF patients 
vs. 0% of controls, P=0.001), steatosis (47% vs. 13%, P=0.028) and portal 
inflammation (21% vs 0%, P=0.088) was increased compared to control samples of 
age-matched liver transplant donors (P<0.05 for all). Entirely normal liver histology 
was found only in six IF patients (16%) with less septic episodes [mean 0.3 septic 
episodes per patient (range 0-2) vs 2.1 (0-10), P=0.009] and longer remaining age-
adjusted small bowel length [mean 79% (range 42-100) vs 35% (3-100), P=0.001] 
compared to patients with abnormal liver histology. When comparing patients with 
SBS and patients with intestinal motility disorders, abnormal liver histology (92% vs 
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71%, P=0.167), including cholestasis (17% vs 14%, P=1.000), steatosis (54% vs 
36%, P=0.328) and fibrosis (83% vs 57%, P=0.127) was found equally (Mutanen et 
al, unpublished results).  
 
Fibrosis (III) 
Liver fibrosis similarly governed liver histology in patients on PN (88%) and patients 
weaned off PN (64%, P=0.143). Fibrosis was focused on portal areas, with 
occasional lobular fibrosis, in both patient groups (Figure 6). Metavir fibrosis stage 
was comparable between patients on PN [mean 1.6 (range 0-4)] and patients 
weaned off PN [1.1 (0-2), P=0.089]. Metavir fibrosis stage associated with age at PN 
start (r=-0.353, P=0.030), duration of PN (r=0.387, P=0.016), time after weaning off 
PN (r=-0.384, P=0.017), absolute (r=-0.486, P=0.002) and percentage of age-
adjusted small bowel length (r=-0.552, P=0.001), ileum length (r=-0.453, P=0.004), 
and number of blood culture positive septic episodes (r=0.480, P=0.002). Moreover, 
patients without ileocaecal valve had more often (20/22 vs 8/16, P=0.008) and more 
advanced liver fibrosis [Metavir fibrosis stage mean 1.6 (range 0-4) vs 0.9 (0-2), 
P=0.034] compared to those with preserved ileocaecal valve. Lobular fibrosis grade 
correlated with ileum length (r=-0.581, P=0.001), duration of PN (r=0.466, P=0.003) 
and absolute (r=-0.334, P=0.035) and age-adjusted colon length (r=-0.391, P=0.015).  
 
Fibrosis Metavir stage associated with ALT (r=0.333, P=0.041), AST (r=0.396, 
P=0.014), but not with bilirubin, albumin or prealbumin (Mutanen A et al, unpublished 
results). Moreover, APRI correlated positively with the Metavir fibrosis stage 
(r=0.404, P=0.013). Age-adjusted small bowel length (P=0.001), grade of portal 
inflammation (P=0.030) and absence of ileocaecal valve (P=0.044) were significant 
predictors of fibrosis Metavir stage in a multivariate stepwise linear regression model 
(R2=0.425). In a multiple logistic regression model the strongest independent 
predictor for fibrosis was absence of ileocaecal valve (OR=8.9, P=0.05). 
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Figure 6. Liver fibrosis in intestinal failure patients is seen in reticulin stainings. Figure A; Fibrosis 
Metavir stage 1 with portal fibrosis without septa, Figure B; fibrosis Metavir stage 2 with portal-portal 
fibrous septa, Figure C; fibrosis Metavir stage 3 with portal-portal and portal-central fibrous septa.  
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Steatosis (III, IV) 
Steatosis was equally common during (in 50% to 60%) and after weaning off PN (in 
50%, P=0.782), including equal amounts of micro- (50%) and macrovesicular (50%) 
steatosis in both groups. Furthermore, grade of steatosis [1 (0-3) vs 0.5 (0-3), 
P=0.571] was comparable during and after weaning off PN (Figure 7). Patients on PN 
had more foamy degeneration compared to those weaned off PN [grade 0.7 (0-3) vs 
0 (0), P=0.044] while no Mallory body formation or hepatocyte apoptosis was 
observed.  
 
In patients with steatosis, portal fibrosis grade [1.6 (0-4) vs 0.6 (0-3), P=0.013] and 
Metavir fibrosis stage [1.6 (0-4) vs 0.7 (0-3), P=0.019] was significantly higher 
compared to those without steatosis while amount of portal inflammation was equal 
between the two groups (P=0.315). Liver steatosis grade associated with portal 
fibrosis grade (r=0.433, P=0.017), Metavir fibrosis stage (r=0.411, P=0.024), duration 
of PN (r=0.471, P=0.009) and absolute (r=-0.502, P=0.005) and age-adjusted (r=-
0.604, P<0.001) remaining small bowel length. Steatosis was unrelated to liver 
biochemistry, weight Z-score, BMI, number of septic episodes, glucose homeostasis 
or serum lipids.  
 
Portal inflammation (III, IV) 
Portal inflammation, consisted mainly of neutrophils and lymphocytes, was more 
common in patients on PN than patients weaned off PN (P=0.050). Portal 
inflammation positively associated with cholestasis (r=0.333, P=0.041) and portal 
fibrosis (r=0.333, P=0.041) but not with steatosis (r=-0.258, P=0.118). Grade of portal 
inflammation associated with liver biochemistry, including ALT (r=0.43, P=0.005), 
AST (r=0.538, P=0.001), GT (r=0.487, P=0.002), APRI (r=0.426, P=0.009), albumin 
(r=-0.465, P=0.005), and prealbumin (r=-0.480, P=0.002), but not with serum lipids, 
glucose homeostasis, or serum creatinine (Mutanen A et al, unpublished results).  
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Figure 7. Steatosis in intestinal failure patients is seen in Periodic acid-Schiff (PAS) stainings. Figure 
A; steatosis grade 1, Figure B; steatosis grade 3.
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Cholestasis (III) 
Cholestasis (Figure 8), including intracellular cholestasis in five (mean grade 1.8, 
range 0-3), canalicular cholestasis in five (mean grade 1.5, range 0-3), and ductular 
cholestasis in one patient (grade 1), was only found in six patients on PN and none of 
the patients weaned off PN. Time after weaning off PN inversely correlated with 
cholestasis grade (r=-0.429, P=0.007). In patients on PN, amount of canalicular 
cholestasis associated with the daily PN glucose dose (g/kg/day; r=0.631, P=0.009), 
but not with total amount of daily PN calories (kcal/kg/day; r=0.421, P=0.104) or PN 
fat (g/kg/day; r=0.022, P=0.934). In addition, the number of weekly PN infusions 
tended to associate with intracellular and intracanalicular cholestasis (r=0.496, 
P=0.051 for both).  
 
As a sign of cholestasis, expression of CK7 in periportal hepatocytes was increased 
in patients on PN. Periportal CK7 expression correlated with remaining ileum length 
(r=-0.347, P=0.041) and number of blood culture positive septic episodes (r=0.421, 
P=0.013). Intracellular and intracanalicular cholestasis positively correlated with liver 
biochemistry, including ALT, GT, AST, total bilirubin, and conjugated bilirubin (P<0.05 
for all). 
 
  
 
Figure 8. Intracellular cholestasis in intestinal failure patient is seen in Copper staining. 
  
 70 
5.10 Serum FGF21 and liver steatosis (IV) 
 
Serum levels of FGF21 were significantly higher in patients [median 299 pg/mL 
(range 21-20345)] compared to controls [133 pg/mL (7-1607), P=0.018]. Frequency 
of liver steatosis (60% vs 50%, P=0.709) and serum FGF21 levels [median 642 
pg/mL (range 76-8473) vs 163 pg/mL (21-20345), P=0.083] were comparable 
between patients on PN and patients weaned off PN. In patients with liver steatosis 
[median 626 pg/mL (range 21-20345)] the serum FGF21 level was six times higher 
compared to patients without steatosis [108 pg/mL (32-568), P=0.002] or healthy 
controls [133 pg/mL (7-1607), P<0.001]. Moreover, the serum FGF21 levels of 
patients without steatosis and healthy controls were comparable (P=0.865).  
 
In patients with mild steatosis (grade 1), serum FGF21 levels were higher [median 
627 pg/mL (range 21-2614)] compared to controls [133 (7-1607), P=0.002]. In 
patients with more advanced liver steatosis (grade 3), the serum FGF21 levels were 
markedly higher compared to patients with a milder steatosis (grade 0 to 2, P≤0.001 
for all). Serum FGF21 level associated to duration of PN (r=0.580, P<0.001), liver 
steatosis grade (r=0.589, P=0.001), remaining age-adjusted small bowel length (r=-
0.368, P=0.029), time after weaning off PN (r=-0.343, P=0.044), prealbumin (r=-
0.416, P=0.022), and INR (r=-0.517, P=0.002). In a multiple stepwise linear 
regression model, including duration of PN, age-adjusted small bowel length and liver 
steatosis grade, the liver steatosis grade (ß=0.630, P=0.001) was predictive for 
serum FGF21 level.  
 
Serum FGF21 level did not associate with fibrosis Metavir stage, APRI, or serum 
citrulline. Furthermore, FGF21 level was unrelated to glucose homeostasis (blood 
fasting glucose, serum insulin, HbA1c, HOMA-IR), liver biochemistry (ALT, AST, GT, 
bilirubin), serum leptin or creatinine, BMI, or weight z-score. In addition, serum 
FGF21 lacked association with the amount of daily parenteral energy (r=0.127, 
P=0.726), fat (r=0.158, P=0.653) or glucose (r=-0.115, P=0.751) in patients receiving 
PN. After weaning off PN, plasma triglyceride levels associated to serum FGF21 
level (r=-0.412, P=0.036).  
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6 Discussion 
 
 
6.1 Methodology 
 
In follow-up study I, all IF patients on long-term PN treated in Children’s Hospital, 
University of Helsinki, volunteered to participate. In follow-up study II, the 
participation of all five Finnish University Hospitals allowed all-inclusive nationwide 
patient identification, as these units treat all neonates and children on long-term PN. 
A high participation rate was reached, as altogether 73% (III) and 67% (IV) of the 
eligible patients participated in the cross-sectional studies. The participant and 
nonparticipant groups were comparable in terms of demographic variables and 
disease characteristics, including age at PN start, duration of PN, remaining bowel 
anatomy, and number of septic episodes, making significant selection bias unlikely 
(III, IV).  
 
The study protocols of follow-up studies (I, II) and cross-sectional studies (III, IV) 
were carefully planned. The procedures needed for sample collection and analysis 
were done in collaboration with experts from different fields, including pediatric 
radiologists (abdominal ultrasound and taking liver biopsy), pediatric pathologists 
(liver biopsy sample evaluation), gastroenterologists (planning serum cholesterol and 
non-cholesterol sterol measurements), and pediatric surgeons (gastroscopy).  
 
Previous reports and clinical experience in Children’s Hospital, Helsinki University 
Central Hospital, have pointed out that abnormalities in liver histology may persist or 
even continue to proceed during and in some cases even after weaning off PN in IF 
patients (Rodgers BM 1976, Cohen C 1981, Dahms BB 1981, Moss RL 1993, 
Hasegawa T 2002, Fitzgibbons SC 2010, Peyret B 2011). Liver histology was 
evaluated in studies I, III, and IV. The ultrasound guided percutaneous core needle 
liver biopsies were taken under general anesthesia, to avoid unnecessary pain, by an 
experienced pediatric radiologist. Two experienced pediatric liver pathologists and 
the primary researcher, blinded to clinical data, analyzed the liver biopsies together 
until consensus was reached to minimize the influence of a single researcher or 
knowledge of clinical data on results. Liver biopsies were thoroughly evaluated 
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according to widely accepted scores, including grading for steatosis, fibrosis, 
cholestasis, bile ductular proliferation, portal inflammation, hepatocyte apoptosis, 
foamy degeneration, Mallory bodies, pseudo-rosettes and extramedullar 
hematopoiesis (Cohen C 1981, Ishak K 1995, Bedossa P 1996, Scheuer PJ 2006, 
Peyret B 2011). 
 
To assess cholesterol metabolism during and after weaning off PN in IF patients, 
measurements of serum cholesterol and non-cholesterol sterols were performed from 
nonsaponifable material by gas-liquid chromatography; allowing measurements of 
markers of cholesterol absorption and synthesis at the same time (I, II). To evaluate 
both cholesterol synthesis and absorption after weaning off PN, and effects of PN on 
serum plant sterols in patients on PN, several serum markers were used, as 
recommended (Miettinen TA 2011). Serum FGF21, previously shown to relate on 
liver steatosis, glucose and lipid metabolism in adults with nonalcoholic 
steatohepatitis (NASH) (Itoh N 2004, Kharitonenkov A 2005, Kharitonenkov A 2007, 
Xu J 2009, Fisher FM 2011), was measured to evaluate its relation to liver steatosis, 
glucose homeostasis, renal function, and lipid metabolism in pediatric onset IF.  
 
A challenge in the studies was the wide age range of patients. Moreover, the 
treatment of IF patients has significantly developed over time. The composition of 
parenteral lipids has changed from soy-based to olive oil- and fish oil-based 
emulsions containing less or no plant sterols, amount of PN fat is limited, and cyclic 
PN infusions and early initiation of enteral nutrition are prefered (Mirtallo J 2004, 
Zambrano E 2004, Pironi L 2012). Furthermore, improved catheter care, awareness 
and aggressive treatment of septic episodes and SIBO, and new surgical 
approaches, have significantly changed the treatment and improved outcomes of IF 
patients (Kelly DA 2006). Although the changes in clinical practice may have 
modulated some of the results and may hamper their applicability for newly treated 
children with IF, these studies provide reliable population-based information 
regarding the current long-term outcomes of liver function and histology in patients 
with pediatric onset IF.  
 
 
 73 
6.2 Incidence of long-term PN and IFALD in neonates and children in Finland  
 
Study II described, for the first time, the incidence of long-term PN and IFALD in 
neonates in a prospective nationwide study population. Of all babies born during the 
follow-up time in Finland 0.05% and off those born before 37 weeks of gestation 
treated in Finnish neonatal intensive care units 2.0% required long-term PN.  
 
IFALD, defined by abnormal liver biochemistry, was found more frequently in 
neonates (63%) compared to children (27%) on long-term PN. The overall survival 
was 89% among neonates on long-term PN as three neonates died from septic 
complications (II). In study III, four of the 56 identified IF patients had died (7%), 
including end-stage liver disease in two and septic complications in two as a cause of 
death, and one patient had esophageal varices and portal hypertension as a sign of 
end-stage liver disease. These results support the previously reported incidence and 
survival rates of PNALD in children on PN, including higher incidence of IFALD in 
neonates (Kelly DA 2006, Pironi L 2012).  
 
 
6.3 Effects of long-term PN on serum lipids, cholesterol and non-cholesterol 
sterols, and liver histology in pediatric onset IF 
 
Serum plant sterols during PN in pediatric onset IF  
As described by Clayton and others, patients receiving PN containing plant sterols 
exhibit increased serum concentrations of plant sterols (Clayton PT 1993, Iyer KR 
1998, Hallikainen M 2008, Llop M 2008). The findings in studies I and II, including 
higher serum plant sterol levels, namely sitosterol, stigmasterol, and avenasterol in 
both children and neonates during PN compared to healthy controls, parallel those 
previously described. The sitosterol levels of children with IF on PN were lower 
compared to those seen in patients with homozygous phytosterolemia, a rare familial 
lipid storage disease leading to accelerated atherosclerosis and sometimes liver 
failure with sitosterol levels up to 1500 µmol/L, but clearly higher than in patients with 
heterozygous phytosterolemia, a clinically symptomless condition with serum 
sitosterol levels <30 µmol/L (Salen G 1992, Miettinen TA 2006). Furthermore, 
neonates on PN had higher serum plant sterol levels compared to older children on 
PN.  
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The distribution of individual plant sterols in the serum closely paralleled that of 
infused lipid regimen in older children with IF during PN. In contrast, in neonates with 
IFALD, the serum levels of plant sterols were weighted with high stigmasterol levels 
during and also after weaning off PN. The parenteral percentage of energy in 
children, and duration of PN in neonates, positively related to serum plant sterol 
levels, namely stigmasterol and avenasterol. In neonates on PN, associations 
between serum plant sterol levels and serum ALT, AST, and direct bilirubin, were 
identified. In contrast, the serum plant sterol levels were unrelated to the amount of 
plant sterols or lipids infused both in children and neonates on PN. Similar findings 
were reported by Ellegård et al (Ellegård L 2005) in adult SBS patients on PN, 
showing high serum levels of plant sterols but no correlation between administration 
of plant sterols and serum plant sterol levels.  
 
PNALD is linked to defects in the bile canalicular ABC-transporter family proteins, 
including the bile salt export pump (BSEP) (Abcb11) and multi-drug resistance 1 and 
2 (mdr1, mdr2) genes encoding P-glycoproteins, responsible for transport of bile 
acids and phospholipids out of hepatocytes (Trauner M 1998, Carter BA 2007, 
Tazuke Y 2009). On the basis of in vitro studies, plant sterol stigmasterol is 
suggested to promote cholestasis through inhibition of nuclear receptor FXR, which 
would further result in reduced hepatocyte expression of a wide variety of FXR-
dependent genes, including Abcb11/BSEP and conjugated bilirubin transporter 
Abcc2 (Trauner M 1998, Carter BA 2007). Moreover, gene knockout mice lacking the 
FXR hepatoprotective mechanisms are ultrasensitive to bile acid-induced liver injury 
and treatment of rats with FXR-agonist protects against cholestasis (Sinal CJ 2000, 
Liu Y 2003). In a mouse model of PNALD combining PN infusions with intestinal 
injury, El Kasmi and co-workers demonstrated that stigmasterol specifically promotes 
cholestasis, liver injury, and liver macrophage activation (El Kasmi KC 2013). These 
changes are likely mediated through suppression of canalicular bile transporter 
expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors 
FXR and LXR and failure of up-regulation of the hepatic sterol exporters (ABCG5/8) 
(El Kasmi KC 2013). The result of studies I and II, showing high levels of serum plant 
sterols, especially stigmasterol during PN, support these in vitro and animal studies 
and further outline the role of parenteral plant sterols, especially stigmasterol, as a 
major contributor in the pathogenesis of IFALD in neonates and children. 
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Because serum plant sterols reflect the balance between input and biliary excretion, 
plant sterols are expected to accumulate in liver damage (Hazard SE 2007). In end-
stage primary biliary cirrhosis, the inability of damaged liver to efficiently excrete plant 
sterols or synthesize cholestanol has been reported (Nikkilä K 2005). High 
cholesterol synthesis is associated with increased biliary cholesterol secretion 
paralleling biliary secretion of sitosterol and campesterol (Sudhop T 2002). In study 
II, children on PN had more increased cholesterol synthesis than neonates on PN, 
which further may have promoted the total increase of serum plant sterols in 
neonates by decreasing their secretion in to bile. In addition, the serum levels of plant 
sterols were more strikingly high when comparing neonates with IFALD and 
neonates without IFALD. After weaning off PN, serum stigmasterol and cholestanol 
levels remained high in neonates with persistent IFALD. These findings further 
emphasise the role of parenteral stigmasterol as a liver damage promoting factor in 
IFALD and suggest that plant sterols, including stigmasterol, accumulate in neonates 
on PN, presumably due to insufficient hepatobiliary excretion capacity. 
 
Serum cholestanol during PN in pediatric onset IF 
Cholestanol is a noncholesterol sterol metabolite of cholesterol that reflects 
cholesterol absorption under physiological conditions and is shown to be a sensitive 
indicator of cholestasis in primary biliary cirrhosis and biliary atresia (Miettinen TA 
1989, Nikkilä K 1991, Gylling H 1996, Nikkilä K 2008, Nissinen MJ 2008, Pakarinen 
MP 2010). In study II on neonates on PN, the relationship between the serum 
cholestanol proportion to cholesterol and bilirubin supports the previous findings, 
suggesting that the serum cholestanol/cholesterol-ratio is a useful marker of 
cholestasis also in IFALD. 
 
Serum cholesterol and cholesterol precursors levels during PN 
Serum cholesterol precursors, including lathosterol, desmosterol and cholestenol, 
are, particularly when expressed as proportions to cholesterol, surrogate markers of 
cholesterol synthesis (Miettinen TA 1990, Nissinen MJ 2008). In study I, the serum 
levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol of children with IF 
were low during PN. At the same time, serum levels of cholesterol precursors, 
including cholestenol, desmosterol, and lathosterol, were high in children with IF on 
 76 
PN compared to healthy controls. In study II on neonates on long-term PN, 
lathosterol to cholesterol proportion was increased compared to healthy controls, but 
lower than in older children on PN. These findings most likely reflect increased 
cholesterol synthesis due to malabsorption of cholesterol and bile acids, and 
insufficiency of PN provided cholesterol to compensate for the intestinal losses in IF.  
 
 
6.4 Characterization of liver histology in pediatric onset IF 
 
Liver histology during PN 
Initially the hepatic histopathology secondary to PN is characterized by cholestasis 
with variable degree of fibrosis and steatosis (Postuma R 1979, Benjamin DR 1981, 
Hodes JE 1982, Quigley EM 1993, Buchman A 2002). In study III, liver histology was 
abnormal in 94% of patients on PN and weighted with cholestasis, portal 
inflammation, fibrosis, and steatosis. Cholestasis, found only in patients on PN, was 
closely associated with portal inflammation, which further outlines the close 
relationship of cholestasis and inflammation in the pathogenesis of liver fibrosis in 
IFALD. Significant or severe fibrosis (Metavir stage ≥2), accompanied by deranged 
liver biochemistry, was found in over half of IF patients on long-term PN. During PN, 
equal amounts of micro- and macrovesicular steatosis, with no associated Mallory 
body formation or apoptosis, were found. Collectively, these findings suggest that 
during PN, histopathological liver changes occur in most patients with pediatric onset 
IF and are characterized by cholestasis, portal infalammation, fibrosis, and steatosis.  
 
Liver histology after weaning off PN 
In most cases, biochemical cholestasis slowly resolves after weaning off PN (Pichler 
J 2010). Previous retrospective studies and case reports on mixed patient 
populations suggest that the liver histology may remain abnormal or even continue to 
progress after weaning off PN (Rodgers BM 1976, Cohen C 1981, Dahms BB 1981, 
Moss RL 1993, Hasegawa T 2002). Results of study II showed, that one month after 
weaning of PN 25% of neonates fulfilled the criteria for IFALD with increased serum 
stigmasterol and cholestanol levels. In study III, abnormal liver histology was found in 
77% of IF patients after weaning off PN an average 8.8 years before. After weaning 
off PN, despite diminishing portal inflammation and resolution of cholestasis, liver 
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fibrosis and steatosis persisted. Interestingly, liver fibrosis was equally common 
during and after weaning off PN with comparable lobular and portal fibrosis grade, 
Metavir fibrosis stage, and steatosis grade. A weak inverse correlation between 
Metavir stage and time after weaning off PN was found suggesting that some 
resolution of fibrosis may occur. Altogether, based on the results of studies III-IV, a 
majority of patients have persistent abnormal liver histology characterized by fibrosis 
and steatosis after weaning off PN.  
 
 
6.5 Serum FGF21 in pediatric onset IF 
 
Serum FGF21 and liver steatosis in pediatric onset IF 
Serum FGF21, a member of the fibroblast growth factor family and a hormone with 
circadian rhythm primarily secreted by the liver, has been shown to regulate glucose 
and lipid metabolism and associate with liver steatosis in experimental animal models 
and in humans (Itoh N 2004, Kharitonenkov A 2005, Kharitonenkov A 2007, Xu J 
2009, Fisher FM 2011, Yu H 2011). In adults with nonalcoholic fatty liver disease 
concentration of circulating FGF21 as well as hepatic FGF21 mRNA and protein 
levels are previously reported to associate with the degree of liver steatosis, 
supporting the role of FGF21 as a biomarker of hepatic lipid accumulation (Li H 
2010). In study IV, serum FGF21 levels reflected hepatic fat accumulation paralleling 
the steatosis grade as patients with more advanced steatosis had higher serum 
FGF21 levels compared to patients with milder steatosis. Patients with steatosis had 
five to six times higher serum FGF21 levels compared to those without steatosis or 
healthy controls. Both serum FGF21 and liver steatosis associated with the duration 
of PN and remaining small bowel length. Liver steatosis stage was found to be the 
only predictor of serum FGF21 level in a multiple regression model. Serum FGF21 
levels and liver steatosis grade were comparable during and after weaning off PN. 
However, time after weaning off PN negatively correlated with serum FGF21 level. 
This suggests, that a recent exposure to PN may relate to higher serum FGF21 
levels. Although, serum FGF21 levels have previously been suggested to decrease 
in advanced liver injury along with progression from steatosis to fibrosis in NASH 
(Dushay J 2010), in pediatric onset IF serum, FGF21 concentration correlated 
positively with INR and negatively with prealbumin suggesting that impaired hepatic 
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function, reflecting hepatocyte injury, was associated with increased serum FGF21 
levels in pediatric onset IF. These findings suggest that increased serum FGF21 
levels reflect liver steatosis, and are associated to the duration of PN and remaining 
small bowel length and may also be a useful marker of liver steatosis in IF associated 
liver steatosis. 
 
Relation of serum FGF21 on glucose homeostasis, serum lipids, renal function and 
liver biochemistry 
In primary human adipocyte cultures, FGF21 has been shown as a potent regulator 
of glucose uptake and insulin sensitivity (Arner P 2008). In patients with impaired 
glucose tolerance, increased FGF21 levels seem to be more closely related to lipid 
metabolism instead of insulin secretion and sensitivity (Li H 2009). FGF21 levels 
have also been shown to depend on renal function in chronic kidney disease (Stein S 
2009, Lin Z 2011). In contrast to previous findings in humans, study IV showed that 
serum levels of FGF21 were unrelated to glucose homeostasis, including fasting 
glucose, serum insulin, HbA1c, and HOMA-IR, or renal function in patients with 
pediatric onset IF. Of note, glucose tolerance, insulin sensitivity and renal function 
were normal in most of IF patients.  
 
In patients with impaired glucose tolerance or NASH, increased serum levels of 
FGF21 are associated with biochemical markers of liver injury, including GT and ALT 
(Li H 2009, Dasarathy S 2011). Moreover, elevated serum FGF21 levels are related 
to hepatocyte apoptosis, increased plasma bile acids and leptin in adult patients with 
NASH (Dasarathy S 2011). In difference to patients with NASH, liver biochemistry or 
serum leptin were not related to serum FGF21 in IF patients.  
 
Previously, serum FGF21 levels have been reported to correlate positively with 
plasma triglycerides and BMI in adult patients with impaired glucose tolerance 
(Chavez AO 2009, Li H 2009). Serum lipids, including cholesterol and triglyceride 
levels, were in low normal range, reflecting most likely cholesterol and fat 
malabsorption in IF patients in studies I and IV. Quite surprisingly, the inverse 
correlation between serum FGF21 and triglyceride levels after weaning off PN was 
the only association between serum lipids and FGF21 in IF patients. In patients with 
IF, FGF21 level was unrelated to weight Z-score or BMI. Based on our findings, 
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serum FGF21 levels are not related to glucose metabolism, renal function, liver 
biochemistry, serum lipids or weight, reinforcing an independent association between 
FGF21 and liver steatosis in patients with pediatric onset IF. 
 
 
6.6 Assessment of liver damage in IF 
 
Liver histology is abnormal in most IF patients during PN and also after weaning off 
PN suggesting that patients with IF need close follow-up considering associated liver 
disease during and after weaning off PN. Although APRI correlated with histological 
liver fibrosis, any of the conventional liver biochemistry, including bilirubin, ALT, AST, 
GT, albumin, prealbumin, blood platelets, INR, were off age-specific normal limits 
only in 63% of patients on PN and in 18% of patients weaned off PN, while liver 
histology was abnormal in 94% of patients on PN and 77% of patients weaned off PN 
in study III. Abdominal ultrasound was abnormal in only four patients. Based on these 
findings, conventional liver biochemistry and abdominal ultrasound alone are 
insufficient for reliable evaluation of liver damage in pediatric onset IF. Liver biopsy 
remains to be the golden standard for evaluation of liver damage in IF during and 
after weaning off PN. Moreover, as shown in study IV, serum FGF21 assay, being 
simple and non-invasive, may be useful in diagnosing IF-associated liver steatosis, 
especially in patients with more advanced steatosis.  
 
 
6.7 Risk factors and prevention of IFALD 
 
Etiology of IFALD is proposed as multifactorial (Kelly DA 2006, Carter BA 2007). 
Various risk factors have been linked to IFALD, but no previous studies are available 
linking association of risk factors of IFALD and histological changes in the liver during 
and after weaning off PN in pediatric onset IF. Based on findings in studies I-IV, the 
etiology of IFALD is multifactorial, including duration, amount and composition of PN, 
parenteral plant sterols, small bowel length, presense/absence of ileocaecal valve, 
septic episodes, and prematurity. (Figure 9) 
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Parenteral plant sterols 
Previous studies have linked high serum levels of plant sterols to IFALD both in 
adults and in children (Clayton PT 1993, Clayton PT 1998, Ellegård L 2005, Llop M 
2008, Hallikainen M 2008), whereas extensive PN fat dose overcoming the ability of 
the liver to clear phospholipids and fatty acids can lead to steatosis, cholestasis, and 
eventually fibrosis (Fizgibbons SC 2010). A lipid dose <1 g/kg/day is found to be 
beneficial in preventing IFALD (Cavicchi M 2000, Mirtallo J 2004). Studies on mice 
have demonstrated that infusion of PN solutions devoid of plant sterols prevent 
cholestasis and liver injury (El Kasmi KC 2013). In contrast, infusion with PN 
emulsion containing stigmasterol as a sole plant sterol produced liver injury and 
cholestasis, despite combination with fish oil (El Kasmi KC 2013). Gene expressions 
of the canalicular bile acid transporter Abcb11 and conjugated bilirubin transporter 
Abcc2 were reduced in mice infused with plant sterol containing PN emulsions while 
serum stigmasterol level correlated with the severity of cholestasis (El Kasmi KC 
2013). In study II, neonates and children with IF receiving olive oil-based PN had 
high levels of serum plant sterols, compared to healthy controls. The serum plant 
sterol distribution reflected their contents in the parenteral lipid emulsion in children 
on PN. In neonates with IFALD, serum levels of plant sterols were high during PN. 
Moreover, after weaning off PN serum stigmasterol and cholestanol levels remained 
high in those neonates with persistent IFALD. Despite the fact that liver biochemistry 
often remained close to normal, the majority of patients had abnormal liver histology 
with high levels of serum plant sterols. A positive correlation was found between 
serum plant sterols and GT and between serum total plant sterols/PN total plant 
sterol-ratio and ALT and bile acids. These results provide evidence that significantly 
increased plant sterol levels, especially that of stigmasterol, may play a significant 
role in pathogenesis of IFALD. The usage of PN lipid emulsions with low plant sterol 
contents, for example, combining olive oil-based and fish oil-based lipid emulsions, 
may be advisable. Serum plant sterol levels can be used to monitor and guide PN 
lipid dosage. A further refinement of diagnostic strategies and mechanisms behind 
IFALD is needed to differentiate the significance of the total PN lipid dosage and total 
and individual plant sterols.  
 
 81 
Bacterial overgrowth and septic episodes 
During and after weaning off PN, SIBO, epithelial changes, and impaired local 
immunity of the small intestine are suggested to cause and maintain liver injury in 
IFALD (Deitch EA 1992, DiBaise JK 2006, Cesaro C 2011). SIBO is induced by the 
loss of barrier function of the ileocaecal valve, dilated bowel segments, and impaired 
motility in patients with intestinal motility disorders or after massive intestinal 
resection (DiBaise JK 2006, Goulet O 2006). PN is shown to increase intestinal 
permeability, promote lipopolysaccharide-activated Toll-like receptor 4-dependent 
Kuppfer cell activation, also suppressing FXR dependent gene pathways, and liver 
injury, presumably caused by bacterial translocation, in mouse model of IF (El Kasmi 
KC 2012). Interestingly, neither intestinal injury nor PN alone was sufficient to induce 
liver injury in the mouse model (El Kasmi KC 2012). Based on results in a mouse 
model, components within the PN solution are suggested to synergize with hepatic 
inflammatory pathways and cytokines that are induced by Toll like receptor agonists, 
such as lipopolysacharides absorbed through an injured intestine with SIBO and 
reduced barrier function, and that activation of Toll like receptor 4-signalling in 
hepatic macrophages leading to generation of proinflammatory cytokines is an 
important component of liver injury in IF (El Kasmi KC 2013). Furthermore, IFALD 
has been shown to be more common in children with recurrent septic episodes 
related to either central line infections or bacterial translocation (Candusso M 2002, 
Heine RG 2002, Kelly DA 2010). In study III, the number of blood culture-positive 
septic episodes, reflecting both central venous catheter and bacterial translocation-
related septic episodes, correlated positively with liver fibrosis and chronic 
cholestasis. Moreover, the patients with the shortest remaining small bowel length 
and those without an ileocaecal valve had the most advanced liver fibrosis. These 
findings outline the contribution of SIBO and septic episodes causing and maintaining 
histological liver damage in IF patients. To preserve liver function and prevent IFALD, 
preserved ileocaecal valve, longer small bowel length, and awareness and 
aggressive treatment of septic episodes and SIBO are beneficial in IF.  
 
Remaining bowel length 
Small intestine exerts liver protection most likely by multifactorial mechanisms, 
including enterohepatic circulation of bile acids (Cavicci M 1998). Short remaining 
intestine length reflects decreased enteral absorption and long-term PN requirements 
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(Goulet O 2006). Moreover, ileal resection is poorly tolerated because of resulting 
malabsorption of bile acids (Youssef NN 2012). In study III, the duration of PN and 
extensive small bowel resection positively correlated with both histological liver 
fibrosis and steatosis. In a multivariate analysis, age-adjusted small bowel length, 
portal inflammation, and absence of an ileocaecal valve were the most significant 
predictors of Metavir fibrosis stage. Interruption of the hepatic circulation, caused by 
resection of the terminal ileum and ICV, exacerbates cholestasis by removing 
negative feedback normally exerted on 7α-hydroxylation of cholesterol, which is the 
rate limiting step in bile acid production (Russel DW 2003). Furthermore, serum 
cholestanol, a marker of cholestasis, correlated positively with serum AST, ALT, 
direct bilirubin, and negatively with the remaining age-adjusted small bowel length in 
neonates on PN in study II supporting this concept. 
  
Prematurity  
In study II, IFALD was more frequent in neonates, especially in those born before 37 
weeks of gestation, compared to children during long-term PN. Parenteral plant 
sterols, especially stigmasterol, seem to accumulate in neonates. Moreover, one 
month after weaning off PN 25% of neonates had persistent IFALD with high 
stigmasterol and cholestanol levels. In study III, liver fibrosis stage was inversely 
related to young starting age of PN. Our findings in neonates are likely to reflect the 
vulnerability and insufficient hepatobiliary excretion capacity of the immature liver of 
the newborn and further support prematurity as risk factor for IFALD. 
 
 
 83 
 
 
 
 
 
 
Figure 9. Factors linked to development of intestinal failure associated liver disease (IFALD). PN; 
parenteral nutrition, ICV; ileocaecal valve. 
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6.8 Future considerations 
 
These studies have showed that a majority of patients with pediatric onset IF have 
abnormal liver histology, including fibrosis and steatosis, during PN but also years 
after weaning off PN. Further studies on the regulation of fibrogenesis and steatosis, 
including studies on matrix metalloproteases and their tissue inhibitors, and 
microarray studies on liver tissue samples, may help to better understand the type of 
the liver injury and to unravel mechanisms causing and maintaining the liver damage 
in IF (Han YP 2006, Hannivoort RA 2012). Studies with longer follow-up and serial 
liver biopsies would help to evaluate the natural history of the liver damage. 
 
Based on the findings of this thesis, conventional liver biochemistry and abdominal 
ultrasound are insufficient for evaluating IFALD. Further prospective studies in 
patients with pediatric onset IF are needed to find noninvasive methods for 
evaluating the liver damage in neonates and children with IF. In this respect, liver 
fibrosis measurement by elastography (FibroScan) may present a promising option 
(de Lédinghen V 2007).  Furthermore, studies on neonates and children with IF on 
serum FGF21, liver histology, and hepatic expression of key regulators of lipid 
metabolism are needed.  
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7 Conclusions 
 
IF and long-term PN are associated with potential life-threatening complications, 
such as IFALD. The aims of these studies were to study epidemiology of long-term 
PN and IFALD, to characterize liver histopathology, and evaluate risk factors of 
IFALD in pediatric onset IF. The effects of parenteral plant sterols on IFALD in 
neonates and children were assessed in two follow-up studies. In the cross-sectional 
studies liver histology was assessed during and after weaning off PN in patients with 
pediatric onset IF. Based on the results of these studies, the following conclusions 
are presented: 
 
1. Of all neonates born in Finland during the one year follow-up period, 0.05% 
required long-term PN. IFALD, defined by abnormal liver biochemistry, was found 
more frequently in neonates (63%) compared to children (27%) on long-term PN. (II) 
 
2. During PN, children with IF have high serum plant sterol levels compared to 
healthy controls. Serum plant sterol distribution reflects their contents in the PN lipid 
emulsions. (I) 
 
3. IFALD is frequent in neonates during PN with an association to markedly 
increased serum plant sterols compared with healthy neonatal controls and children 
on PN with more mature liver function. The high level of serum plant sterols suggest 
that plant sterols, especially stigmasterol, accumulate in neonates on PN, 
presumably due to insufficient hepatobiliary excretion capacity. After discontinuation 
of PN, serum stigmasterol level remains high in neonates with IFALD. Elevated 
serum plant sterol levels, especially stigmasterol, may be an independent risk factor 
for IFALD. (II) 
 
4. During PN, liver histology is characterized by cholestasis, portal inflammation, liver 
fibrosis and steatosis in patients with pediatric onset IF. Over half of the patients on 
long-term PN have significant or severe liver fibrosis accompanied with abnormal 
liver biochemistry. (III) 
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5. Despite diminishing portal inflammation and resolution of cholestasis, liver 
histology remains abnormal up to 9 years after weaning off PN in the majority of IF 
patients. After weaning off PN, the liver histology is characterized by liver fibrosis and 
steatosis. (III) 
 
6. In addition to duration of PN, extensive small intestinal resection and loss of 
ileocaecal valve as well as septic episodes are major risk factors of histological liver 
fibrosis. (III) 
 
7. Increased serum FGF21 levels reflect the presence and the degree of liver 
steatosis in patients with pediatric onset IF. Both serum FGF21 levels and liver 
steatosis exclusively associate with the duration of PN and remaining small bowel 
length; whereas hepatic fat accumulation is a major predictor of increased serum 
FGF21 concentration. (IV) 
 87 
Acknowledgements 
 
 
These studies were carried out in 2009-2013 at the Children’s Hospital, Helsinki 
University Central Hospital, University of Helsinki, and the Departments of Pediatrics 
of University Central Hospitals in Tampere, Turku, Kuopio and Oulu. I wish to thank 
Docent Jari Petäjä, Professors Risto Rintala, Mikael Knip and Markku Heikinheimo 
for providing exellent research facilities and creating a supportive research 
environment. 
 
I had the priviledge to join the National Graduate School of Clinical Investigation 
(CLIGS) and Pediatric Graduate School, which both provided me with valuable 
scientific edecation, financial support, and exellent working facilities at Biomedicum 
2. I warmly thank Professor Markku Heikinheimo, former director of the CLIGS, and 
Docent Jussi Merenmies and Professor Antti Mäkitie, the present directors of the 
graduate schools, for their valuable work and support for young investigators. 
 
I thank financial supporters of these studies: the Finnish Mediacal Foundation, the 
Finnish Pediatric Research Foundation, the Sigrid Juselius Foundation, the Mary and 
Georg C. Ehnroth Foundation, the Päivikki and Sakari Sohlberg Foundation, the 
Foundation for Gastroenterologic Research, the Finnish Association of Pediatric 
Surgeons Sulamaa Society, and the National Graduate School for Clinical 
Investigation.  
 
I warmly thank all patients and their families for participating in these studies. 
 
I am grateful to my outstanding supervisor, Docent Mikko Pakarinen, for introducing 
me to the fascinating world of scientific research, and guiding and supporting me 
through these years. Mikko, your enormous expertise and enthusiasm for pediatric 
surgery research and clinical work are admirable. 
 
I express my sincere gratitude to the official reviewers of this thesis, Docent Taina 
Sipponen and Docent Harri Niinikoski, for their valuable comments and advice. I am 
grateful to the members of my thesis follow-up group, Docent Kaija-Leena Kolho and 
 88 
Docent Markku Nissinen. Kaija-Leena, I thank you for the fruitful discussions and 
encounragament. Markku, I am greatful for your support and of sharing your 
expertise in the field of cholesterol metabolism. 
 
I have had a great opportunity to work with many experts from different fields during 
this study. I am greateful for pathologists, Docent Jouko Lohi and Docent Päivi 
Heikkilä, for introducing me to the facinating world of liver histopathology; Thank you 
for teaching me hands on the principles of liver biopsy interpretation. I thank 
Professor Helena Gylling and late Professor Tatu Miettinen for sharing your 
knowledge on lipid metabolism; Professor Hannu Jalanko for support and helpful 
comments on pediatric hepatology; Professor Taneli Raivio for your instructive 
comments and discussions on FGF21; Docent Antti Koivusalo for encouraging and 
supporting discussions; Professor Sture Andersson, Doctor Päivi Korhonen, Docent 
Tarja Ruuska, Doctor Mari Taimisto, Docent Marko Kalliomäki, Docent Liisa 
Lehtonen, Docent Ulla Sankilampi, Doctor Pekka Arikoski, Doctor Timo Saarela for 
great collaboration in gathering nationwide data on long-term PN; pediatric 
radiologists Kirsi Lauerma, Reetta Kivisaari and Raija Seuri from the Medical Imaging 
Centre for carrying out the abdominal ultrasound exams and ultrasound-quided liver 
needle biopsies; Docent Jouni Lauronen for support at the beginning of my research 
career; Leena Kaipiainen for the gas-liguid chromatopgraphy analyses; staff in the 
surgical departments LK6 and LK5 and outpatient surgery unit, especially Satu 
Kiesvaara, Maija Tuominen, Leena Rusama, Mervi Mannonen, and Eila Hämäläinen, 
for help in arranging patient visits; Kirsi Vaaralahti from Biomedicum Helsinki, 
Institute of Biomedicine/Physiology, for performing the laboratory measurements of 
serum FGF21.  
 
I express my gratitude for Professor Risto Rintala for encouraging young doctors into 
research and to travel abroad to present results at international meetings. Special 
thanks to all the young investigators, Janne, Kristiina, Hanna, Silja K, Topi, Silja V, 
Anna, Malla, and Valtter, for collaboration and great company while abroad. 
 
I thank all research fellows on the 6th floor in Biomedicum 2 for their company and 
discussions during these years. I thank all my colleagues at the Department of 
 89 
Surgery in Päijät-Häme Central Hospital for their collaboration and support in 
combining clinical work and research while working there through these years.  
 
I want to thank all my friends outside of work; especially Leena, Satu, Jatta, Anu, 
Heidi, Jonna and Anni for their true friendship and support, and friends form Joensuu 
for numerous shared joyful moments.  
 
Warm thanks to my dear parents, Leena and Tapani Kurvinen, for their support and 
unconditional love.   
 
Finally, my beloved husband Hannu, thank you for your love, support, patience, 
encouragement, and for always being there for me.  
 
 
Annika 
Helsinki, March 2014 
 90 
References 
 
Amin SC, Pappas C, Iyengar H, Maheshwari A. Short bowel syndrome in the NICU. 
Clin Perinatol 2013;40:53-68. 
 
Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson DS, Collier SB, 
Lo C, Duggan C. Nutritional and other postoperative management of neonates 
with short bowel syndrome correlates with clinical outcomes. J Pediatr 
2001;139:27-33. 
 
Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic 
regulators –a critical appraisal. Cell Metab 2012;16:693-705. 
 
Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. FGF21 
attenuates lipolysis in human adipocytes – a possible link to improved insulin 
sensitivity. FEBS Lett 2008;582:1725-1730. 
 
Atia A, Girard-Pipau F, Hébuterne X, Spies WG, Guardiola A, Ahn CW, Fryer J, Xue 
F, Rammohan M, Sumague M, Englyst K, Buchman AL. Macronutrient 
characteristics in humans with short bowel syndrome and jejunocolic 
anastomosis: starch is the most important carbohydrate substrate, although 
pectin supplementation may modestly enhance short chain fatty acid production 
and fluid absorption. J Parenter Enteral Nutr 2011;35:229-240. 
 
Avitzur Y, Grant D. Intestine transplantation in children: update 2010. Pediatr Clin 
North Am 2010;57:415-431. 
 
Bailly-Botuha C, Colomb V, Thioulouse E, Berthe MC, Garcette K, Dubern B, Goulet 
O, Couderc R, Gigardet JP. Plasma citrulline concentration reflects enterocyte 
mass in children with short bowel syndrome. Peditr Res 2009;65:559-563. 
 
Bakker H, Bozzetti F, Staun M, Leon-Sanz M, Hebuterne X, Pertkiewicz M, Shaffer J, 
Thul P. Home parenteral nutrition in adults: a European multicentre survey in 
1997. ESPEN-Home artificial nutrition working group. Clin Nutr 1999;18:135-140. 
 
Bakonyi NA, Takegawa B, Ortolan E, Galvão F, Mendonça F, Sbragia L, Crepaldi N, 
Vicente Y, Chaves H, Guimarães J. Demographic of short gut syndrome: 
increasing demands is not followed by referral of potential candidates for small 
bowel transplantation. Transplant Proc 2004;36:259-260. 
 
Baksheev L, Fuller PJ. Humoral factors in intestinal adaptation. Trends Endocrinol 
Metab 2000;11:401-405. 
 
Beale EF, Nelson RM, Bucciarelli RL, Donnelly WH, Eitzman DV. Intrahepatic 
cholestasis associated with parenteral nutrition in premature infants. Pediatrics 
1979;64:342-347. 
 
Beath S, Pironi L, Gabe S, Horslen S, Sudan D, Mazeriegos G, Steiger E, Goulet O, 
Fryer J. Collaborative strategies to reduce mortality and morbidity in patients with 
 91 
chronic intestinal failure including those who are referred for small bowel 
transplantation. Transplantation 2008;85:1378-1384. 
 
Beath SV, Davies P, Papadopoulou A, Khan AR, Buick RG, Corkery JJ, Gornall P, 
Booth IW. Parenteral nutrition-related cholestasis in postsurgical neonates: 
multivariate analysis of risk factors. J Pediatr Surg 1996;31:604-606. 
 
Bedossa P, Poynard T. An algorithm for the grading of activity of chronic hepatitis C. 
The METAVIR cooperative study group. Hepatology 1996;24:289-293. 
 
Benhamou PH, Canarelli JP, Richard S, Cordonnier C, Postel JP, Grenier E, Leke A, 
Dupont C. Human recombinant growth hormone increases bowel lengthening 
after massive small bowel resection in piglets. J Pediatr Surg 1997;32:1332-1336. 
 
Benjamin DR. Hepatobiliary dysfunction in infants and children associated with long-
term total parenteral nutrition. A clinico-pathologic study. Am J Clin Pathol 
1981;76:276-283. 
 
Bianchi A. Intestinal loop lengthening – A technique for increasing small intestinal 
length. J Pediatr Surg 1980;15:145-151. 
 
Bines JE. Intestinal failure: a new era in clinical management. J Gastroenterol 
Hepatol 2009;24:S86-92. 
 
Bond GJ, Reyes JD. Intestinal transplantation for total/near-total aganglionosis and 
pseudo-obstruction in children. Semin Pediatr Surg 2004;13:286-292. 
 
Braxton C, Lowry SF. Parenteral nutrition and liver dysfunction – new insight? J 
Parenter Enteral Nutr 1995;19:3-4. 
 
Briet F, Flourié B, Achour L, Maurel M, Rambaud JC, Messing B. Bacterial 
adaptation in patients with short bowel and colon in continuity. Gastroenterology 
1995;109:1446-1453. 
 
Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. 
Pharmacotherapy 2002;22:188-211. 
 
Buchman A. Total parenteral nutrition-associated liver disease. J Parenter Enteral 
Nutr 2002;26:S43-48. 
 
Buchman AL, Moukarzel AA, Bhuta S, Belle M, Ament ME, Eckhert CD, Hollander D, 
Gornbein J, Kopple JD, Vijayaroghavan SR. Parenteral nutrition is associated 
with intestinal morphologic and functional changes in humans. J Parenter Enteral 
Nutr 1995;19:453-460. 
 
Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome 
and intestinal transplantation. Gastroenterology 2003;124:1111-1134. 
 
Bueno J, Ohwada S, Kocoshis S, Mazariegos GV, Dvorchik I, Sigurdsson L, Di 
Lorenzo C, Abu-Elmagd K, Reyes J. Factors impacting the survival of children 
 92 
with intestinal failure referred for intestinal transplantation. J Pediatr Surg 
1999;34:27-32. 
 
Candusso M, Faraguna D, Sperli D, Dodaro N. Outcome and quality of life in 
paediatric home parenteral nutrition. Curr Opin Clin Nutr Metab Care 2002;5:309-
314. 
 
Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and 
treatment strategies past, present, and future. Semin Liver Dis 2007;27:251-258. 
 
Carter BA, Taylor OA, Prendergast DR, Zimmerman TL, Von Furstenberg R, Moore 
DD, Karpen SJ. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of 
the bile acid nuclear receptor FXR. Pediatr Res 2007;62:301-306. 
 
Casey L, Lee KH, Rosychuk R, Turner J, Huynh HQ. 10-year review of pediatric 
intestinal failure: clinical factors associated with outcome. Nutr Clin Pract 
2008;23:436-442. 
 
Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and 
contributing factors in patients receiving home parenteral nutrition for permanent 
intestinal failure. Ann Inter Med 2000;132:525-532. 
 
Cavicchi M, Crenn P, Beau P, Degott C, Boutron MC, Messing B. Severe liver 
complications associated with long-term parenteral nutrition are dependent on 
lipid parenteral input. Transplat Proc 1998;30:2547. 
 
Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco 
C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver 
Dis 2011;43:431-438. 
 
Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, Forse RA, 
Babineau T, Burke P. Incidence, prognosis, and ethiology of end-stage liver 
disease in patients receiving home total parenteral nutrition. Surgery 
1999;126:28-34. 
 
Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. 
Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance 
and type 2 diabetes and correlates with muscle and hepatic insulin resistance. 
Diabetes Care 2009;32:1542-1546. 
 
Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Boden G. Circulating FGF-21 
levels in normal subjects and in newly diagnosed patients with Type 2 diabetes 
mellitus. Exp Clin Endocrinol Diabetes 2008;116:65-68. 
 
Chernoff R. An overview of tube feeding: from ancient times to the future. Nutr Clin 
Pract 2006;21:408-410. 
 
Chitkara DK, Di Lorenzo C. From the bench to the crib-side: implications of scientific 
advances to paediatric neurogastroenterology and motility. Neurogatroenterol 
Motil 2006;18:251-262. 
 93 
Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK. Identifying 
patients, on the first day of life, at high-risk of developing parenteral nutrition 
associated liver disease. J Perinatol 2007;27:284-290. 
 
Chumpitazi B, Nurko S. Pediatric gastrointestinal motility disorders: challenges and a 
clinical update. Gastroenterol Hepatol 2008;4:140-148. 
 
Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, Milla PJ. Phytosterolemia 
in children with parenteral nutrition-associated cholestatic liver disease. 
Gastroenterology 1993;105:1806–1813. 
 
Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver 
complications of pediatric parenteral nutrition. Nutrition 1998;14:158-164. 
 
Cober MP, Killu G, Brattain A, Welch KB, Kunisaki SM, Teitelbaum DH. Intravenous 
fat emulsions reduction for patients with parenteral nutrition-associated liver 
disease. J Pediatr 2012;160:421-427. 
 
Cober MP, Teitelbaum DH. Prevention of parenteral nutrition-associated liver 
disease: lipid minimization. Curr Opin Organ Transplant 2010;15:330-333. 
 
Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention 
of central venous access device infections in pediatric patients with intestinal 
failure. J Parenter Enteral Nutr 2011;35:67-73. 
 
Cohen C, Olsen MM. Pediatric total parenteral nutrition. Liver histopathology. Arch 
Pathol Lab Med 1981;105:152-156. 
 
Cole CR, Frem JC, Schmotzer B, Gewirtz AT, Meddings JB, Gold DB, Ziegler TR. 
The rate of bloodstream infections is high in infants with short bowel syndrome: 
relationship with small bowel bacterial over growth, enteral feeding, and 
inflammatory and immune responses. J Pediatr 2010;156:941-947. 
 
Cole CR, Hansen NI, Higgins RD, Ziegler TR, Stoll BJ, Eunice Kennedy Shiver 
NICHD Neonatal Research Network. Very low birth weight preterm infants with 
surgical short bowel syndrome: incidence, morbidity and mortality, and growth 
outcomes at 18 and 22 months. Pediatrics 2008;122:e573-582. 
 
Colomb V, Dabbas-Tyan M, Taupin P, Talbotec C, Révillon Y, Jan D, De potter S, 
Gorski-Colin AM, Lamor M, Herreman K, Corriol O, Landais P, Ricour C, Goulet 
O. Long-term outcome of children receiving home parenteral nutrition: a 20-year 
single-center experience in 302 patients. J Pediatr Gastroenterol Nutr 
2007;44:347-353. 
 
Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and 
management. Gastroenterology 2006;130:S29-36. 
 
Cowles RA, Ventura KA, Martinez M, Lobritto SJ, Harren PA, Brodlie S, Carroll J, Jan 
DM. Reversal of intestinal failure-associated liver disease in infants and children 
 94 
on parenteral nutrition: experience with 93 patients at referral center for intestinal 
rehabilitation. J Pediatr Surg 2010;45:84-87. 
 
D’Antiga L, Goulet O. Intestinal failure in children: the European view. J Pediatr 
Gastroenterol Nutr 2013;56:118-126. 
 
Dahms BB, Halpin TC Jr. Serial liver biopsies in parenteral nutrition-associated 
cholestasis of early infancy. Gastroenterology 1981;81:136-144. 
 
Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. 
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and 
fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 
2011;23:382-388. 
 
de Lédinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, Castéra 
L, Sandrin L, Merrouche W, Lavrand F, Lamireau T. Liver stiffness measurement 
in children using FibroScan: feasibility study and comparison with Fibrotest, 
aspartate transaminase to platelets ration index, and liver biopsy. J Pediatr 
Gastroenterol Nutr 2007;45:443-450. 
 
Deitch EA, Xu D, Qi L, Specian RD, Berg RD. Protein malnutrition alone and in 
combination with endotoxin impairs systemic and gut-associated immunity. J 
Parenter Enteral Nutr 1992;16:25-31. 
 
DeLegge M, Alsolaiman MM, Barbour E, Bassas S, Siddiqi MF, Moore NM. Short 
bowel syndrome: parenteral nutrition versus intestinal transplantation. Where are 
we today? Dig Dis Sci 2007;52:876-892. 
 
Dellert SF, Farrell MK, Specker BL, Heubi JE. Bone mineral content in children with 
short bowel syndrome after discontinuation of parenteral nutrition. J Pediatr 
1998;132:516-519. 
 
Diamond IR, de Silva N, Pencharz PB, Kim JH, Wales PW. Neonatal short bowel 
syndrome outcomes after the establishment of the first Canadian multidisciplinary 
intestinal rehabilitation program: preliminary experience. J Pediatr Surg 
2007;42:806-811. 
 
DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel 
syndrome: part 2. Am J Gastroenterol 2004;99:1823-1832. 
 
DiBaise JK, Yuong RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, 
and short-bowel syndrome. Clin Gastroenterol Hepatol 2006;4:11-20. 
 
Dicken BJ, Sergi C, Rescorla FJ, Breckler F, Sigalet D. Medical management of 
motility disorders in patients with intestinal failure: a focus on necrotizing 
enterocolitis, gastroschisis, and intestinal atresia. J Pediatr Surg 2011;46:1618-
1630. 
 
Di Lorenzo C, Youssef N. Diagnosis and management of intestinal motility disorders. 
Semin Pediatr Surg 2010;19:50-58. 
 95 
Di Lorenzo C. Pseudo-obstruction: current approaches. Gastroenterology 
1999;116:980-987 
 
Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001;86:1759-1764. 
 
Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Can intravenous feeding as the sole 
means of nutrition support growth in the child and restore weight loss in adult? An 
affirmative answer. Ann Surg 1969;169:974-984. 
 
Duro D, Kamin D, Duggan C. Overview of pediatric short bowel syndrome. J Pediatr 
Gastroenterol Nutr 2008;47:S33-36. 
 
Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, 
Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth 
factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 
2010;139:456-463. 
 
El Kasmi KC, Anderson AL, Devereaux MW, Fillon SA, Harris JK, Lovell MA, 
Finegold MJ, Sokol RJ. Toll-like receptor 4-dependent Kupffer cell activation and 
liver injury in a novel mouse model of parenteral nutrition and intestinal injury. 
Hepatology 2012;55:1518-1528. 
 
El Kasmi KC, Anderson AL, Devereaux MW, Vue PM, Zhang W, Setchell KD, Karpen 
SJ, Sokol RJ. Phytosterols promote liver injury and kuppfer cell activation in 
parenteral nutrition-associated liver disease. Sci Transl Med 2013;9:206ra137 
 
Ellegård L, Sunesson A, Bosaeus I. High serum phytosterol levels in short bowel 
patients on parenteral nutrition support. Clin Nutr 2005;24:415-420. 
 
Finkel Y. Causes of intestinal failure in the newborn. In: Lagnas AN, Goulet O, 
Quigley EMM, Tappenden KA, eds. Intestinal failure: diagnosis, management and 
transplantation. Volume 1, 1st ed. Oxford: Blackwell publishing ltd, 2008;66-76. 
 
Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, Kharitonenkov A, 
Spiegelman BM, Maratos-Flier E. Integrated regulation of hepatic metabolism by 
fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011;152:2996-3004. 
 
Fishbein TM, Matsumoto CS. Intestinal replacement therapy: timing and indications 
for referral of patients to an intestinal rehabilitation and transplantation program. 
Gastroenterology 2006;130:S147-151. 
 
Fitzgibbons SC, Jones BA, Hull MA, Zurakowski D, Duro D, Duggan C, Boctor D, 
Sigalet DL, Jaksic T. Relationship between biopsy-proven parenteral nutrition-
associated liver fibrosis and biochemical cholestasis in children with short bowel 
syndrome. J Pediatr Surg 2010;45:95-99. 
 
Forchelli ML, Walker WA. Nutritional factors contributing to the development of 
cholestasis during total parenteral nutrition. Adv Pediatr 2003;50:245-267. 
 
 96 
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of preparative 
ultracentrifuge. Clin Chem 1972;18:499-502. 
 
Gabe SM. Lipids and liver dysfunction in patients receiving parenteral nutrition. Curr 
Opin Clin Nutr Metab Care 2013;16:150-155. 
 
Gentile NM, Murray JA, Pardi DS. Autoimmune enteropathy: a review and update of 
clinical management. Curr Gastroenterol Rep 2012;14:380-385. 
 
Goday PS. Short bowel syndrome: how short is too short? Clin Perinatol 
2009;36:101-110. 
 
Goulet O, Baglin-Gobet S, Talbotec C, Fourcade L, Colomb V, Sauvat F, Jais JP, 
Michel JL, Jan D, Ricour C. Outcome and long-term growth after extensive small 
bowel resection in the neonatal period: a survey of 87 children. Eur J Pediatr Surg 
2005;15:95-101. 
 
Goulet O, Ruemmele F, Lacaille F, Colomb V. Irreversible intestinal failure. J Pediart 
Gastroenterol Nutr 2004;38:250-269. 
 
Goulet O, Ruemmele F. Causes and management of intestinal failure in children. 
Gastroenterology 2006;130:S16-28. 
 
Greenberg GR, Wolman SL, Christofides ND, Bloom SR, Jeejeebhoy KN. Effect of 
total parenteral nutrition on gut hormone release in humans. Gastroenterology 
1981;80:988-993. 
 
Guarino A, De Marco G. Italian national network for pediatric intestinal failure. Natural 
history of intestinal failure, investigated through a national network-based 
approach. J Pediatr Gastroenterol Nutr 2003;37:136-141. 
 
Gupte GL, Beath SV, Protheroe S, Murphy MS, Davies P, Sharif K, McKiernan PJ, 
de Ville de Goyet J, Booth IW, Kelly DA. Improved outcome of referrals for 
intestinal transplantation in the UK. Arch Dis Child 2007;92:147-152. 
 
Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, 
Lopes S, Duggan C, Puder M. Safety and efficacy of fish-oil-based fat emulsion in 
the treatment of parenteral nutrition-associated liver disease. Pediatrics 
2008;121:e678-686. 
 
Gutierrez IM, Kang KH, Jaksic T. Neonatal short bowel syndrome. Semin Fetal 
Neonatal Med 2011;16:157-163. 
 
Gylling H, Vuoristo M, Färkkilä M, Miettinen TA. The metabolism of cholestanol in 
primary biliary cirrhosis. J Hepatol 1996;24:444-451. 
 
Hallikainen M, Huikko L, Kontra K, Nissinen M, Piironen V, Miettinen T, Gylling H. 
Effect of parenteral plant sterols on liver enzymes and cholesterol metabolism in a 
patient with short bowel syndrome. Nutr Clin Pract 2008;23:429-435. 
 97 
Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J 
Gastroenterol Hepatol 2006;21:S88-S91. 
 
Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteonomics in 
liver fibrosis and cirrhosis. Fibrogenesis and Tissue Repair 2012;5:1. 
 
Harkness L. The history of enteral nutrition therapy: from raw eggs and nasal tubes 
to purified amino acids and early postoperative jejunal delivery. J Am Diet Assoc 
2002;102:399-404. 
 
Hasegawa T, Sasaki T, Kimura T, Nakai H, Sando K, Wasa M, Takagi Y, Mushiake 
S, Harada T. Effects of isolated small bowel transplantation on liver dysfunction 
caused by intestinal failure and long-term total parenteral nutrition. Pediatr 
Transplantation 2002;6:235-239. 
 
Hazard SE, Patel SB. Sterolins ABCG5 and ABCG8. Regulators of whole body 
dietary sterols. Pflugers Arch 2007;435:745-752. 
 
Heine RG, Bines JE. New approaches to parenteral nutrition in infants and children. J 
Paediatr Child Health 2002;38:433-437. 
 
Heneyke S, Smith VV, Spitz L, Milla PJ. Chronic intestinal pseudo-obstruction in 
children: treatment and long-term follow up in 44 children. Arc Dis Child 
1999;81:21-27. 
 
Hess RA, Welch KB, Brown PI, Teitelbaum DH. Survival outcomes of pediatric 
intestinal failure patients: analysis of factors contributing to improve survival over 
the past two decades. J Surg Res 2011;170:27-31. 
 
Hodes JE, Grosfeld JL, Weber TR, Schreiner RL, Fitzgerald JF, Mirkin LD. Hepatic 
failure in infats on total parenteral nutrition (TPN): clinical and histopathologic 
observation. J Pediatr Surg 1982;17:463-468. 
 
Howard L, Ament M, Fleming CR, Shike M, Steiger E. Current use and clinical 
outcome of home parenteral and enteral nutrition therapies in the United States. 
Gastroenterology 1995;109:355-365. 
 
Ishak K, Baptista A, Bianchi L, Callea F, de Groote J, Gudat F, Denk H, Desmet V, 
Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J 
Hepatol 1995;22:696-699. 
 
Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 
2004;20:563-569. 
 
Iyer KR, Spitz L, Clayton P. New insight into mechanism of parenteral nutrition-
associated cholestasis: role of plant sterols. J Pediatr Surg 1998;33:1-6. 
 
Jeppesen PB. The non-surgical treatment of adult patients with short bowel 
syndrome. Expert Opinion on Orphan Drugs 2013;1:527-538. 
 98 
Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, 
Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 
improves nutrient absorption and nutritional status in short-bowel patients with no 
colon. Gastroenterology 2001;120:806-815. 
 
Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal 
energy and wet weight absorption. Gut 2000;46:701-706. 
 
Jeppesen PB, Mortensen PB. Enhancing bowel adaptation in short bowel syndrome. 
Curr Gastroenterol Rep 2002;4:338-347. 
 
Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O’Keefe SJ, Forbes A, 
Heinze H, Joelsson B. Tedugutide reduces need for parenteral support among 
patients with short bowel syndrome with intestinal failure. Gastroenterology 
2012;143:1473-1481. 
 
Jones BA, Hull MA, McGuire MM, Kim HB. Autologous intestinal reconstruction 
surgery. Semin Pediatr Surg 2010;19:59-67. 
 
Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal 
metabolism in liver. Annu Rev Nutr 1996;16:179-203. 
 
Kaufman SS, Loseke CA, Lupo JV, Young RJ, Murray ND, Pinch LW, Vanderhoof 
JA. Influence of bacterial overgrowth and intestinal inflammation on duration of 
parenteral nutrition in children with short bowel syndrome. J Pediatr 
1997;131:356-361. 
 
Kaufman SS. Prevention of parenteral nutrition-associated liver disease in children. 
Pediatr Transplant 2002;6:37-42. 
 
Kelly DA. Intestinal failure-associated liver disease: what do we know today? 
Gastroenterology 2006;130:S70-77. 
 
Kelly DA. Preventing parenteral nutrition liver disease. Early Hum Dev 2010;86:683-
687. 
 
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, 
Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, 
Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. 
FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-1635. 
 
Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, 
Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is 
regulated by fibroblast growth factor-21. Endocrinology 2007;148:774-781. 
 
Kim HB, Fauza D, Garza J, Oh JT, Nurko S, Jaksic T. Serial transverse enteroplasty 
(STEP): a novel bowel lengthening procedure. J Pediatr Surg 2003;38:425-429. 
 
Kocoshis SA. Medical management of pediatric intestinal failure. Semin Pediatr Surg 
2010;19:20-26. 
 99 
Koffeman GI, van Gemert WG, George EK, Veenendaal RA. Classification, 
epidemiology and aetiology. Best Pract Res Clin Gastroenterol 2003;17:879-893. 
 
Kohl M, Wedel T, Entenmann A, Stuttmann J, Bendiks M, Loff S, Köster S, Ortfeld S, 
Bos I. Influence of different intravenous lipid emulsions on hepatobiliary 
dysfunction in a rabbit model. J Pediatr Gastroenterol Nutr 2007;44:237-244. 
 
Kumpf VJ. Parenteral nutrition-associated liver disease in adult and pediatric 
patients. Nutr Clin Pract 2006;21:279–90. 
 
Lagnas A. The history of intestinal failure and transplantation. In: Lagnas A, Goulet 
O, Quiley EMM, Tappeden KA, eds. Intestinal failure: Diagnosis, management 
and transplantation. Volume 1, 1st ed. Oxford: Blackwell Publishing 2008;3-10. 
 
Lauriti G, Zani A, Aufieri R, Cananzi M, Chiesa PL, Eaton S, Pierro A. Incidence, 
prevention, and treatment of parenteral nutrition-associated cholestasis and 
intestinal failure-associated liver disease in infants and children: a systematic 
review. J Parenter Enteral Nutr 2014;38:70-85. 
  
Lefkowitch JH. Choise of stains. In: Lefkowitch JH, eds. Scheuer’s Liver biopsy 
interpretation. Volume 1. 8th ed. Philadelphia: Elsevier Saunders;2010:11-16. 
 
Lefkowitch JH. The normal liver. In: Lefkowitch JH, eds. Scheuer’s Liver biopsy 
interpretation. Volume 1. 8th ed. Philadelphia: Elsevier Saunders;2010:17-28. 
 
Lehtonen HJ, Sipponen T, Tojkander S, Karikoski R, Järvinen H, Laing NG, 
Lappalainen P, Aaltonen LA, Tuupanen S. Segregation of a missense variant in 
enteric smooth muscle actin γ-2 with autosomal dominant familial visceral 
myopathy. Gastroenterology 2012;143:1482-1491. 
 
Leonberg BL, Chuang E, Eicher P, Tershakovec AM, Leonard L, Stallings VA. Long-
term growth and development in children after home parenteral nutrition. J Pediatr 
1998;132:461-466. 
 
L’Heureux MC, Brubaker PL. Therapeutic potential of the intestinotrophic hormone, 
glucagon-like peptide-2. Ann Med 2001;33:229-235. 
 
Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblast growth 
factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase 
but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 
2009;94:2151-2156. 
 
Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu 
A, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty 
liver disease patients and are correlated with hepatic triglyceride. J Hepatol 
2010;53:934-940. 
 
Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, Feng W, Li X. 
Circulating FGF21 levels are progressively increased from the early to end stages 
 100
of chronic kidney diseases and are associated with renal function in Chinese. 
PloS One 2011;15:e18398. 
 
Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, MacKenzie KI, Mansfield TA, Kliewer 
SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid x receptor agonist 
GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 
2003;112:1678-1687. 
 
Llop M, Virgili N, Moreno-Villares JM, Garcia-Peris P, Serrano T, Forga M, Solanich 
J, Pita AM. Phytosterolemia in parenteral nutrition patients: implications for liver 
disease development. Nutrition 2008;24:1145–1152. 
 
Loff S, Kränzlin B, Moghadam M, Dzakovic A, Wessel L, Back W, Hosie S, Wirth H, 
Waag KL. Parenteral nutrition-induced hepatobiliary dysfunction in infants and 
prepubertal rabbits. Pediatr Surg Int 1999;15:479-482. 
 
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta cell function from 
fasting plasma glucose and insulin concentration in man. Diabetologia 
1985;28:412-419. 
 
Mazariegos GV, Squires RH, Sindhi RK. Current perspectives on pediatric intestinal 
transplantation. Curr Gastroenterol Rep 2009;11:226-233. 
 
Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. 
Long-term survival and parenteral nutrition dependence in adult patients with the 
short bowel syndrome. Gastroenterology 1999;117:1043-1050. 
 
Mian SI, Dutta S, Le B, Esquivel Co, Davis K, Castillo RO. Factors affecting survival 
to intestinal transplantation in the very young pediatric patient. Transplantation 
2008;85:1287-1289. 
 
Miettinen TA, Gylling H, Nissinen MJ. The role of serum noncholesterol sterols as 
surrogate markers of absolute cholesterol synthesis and absorption. Nutr Metab 
Cardiovasc Dis 2011;21:765-769. 
 
Miettinen TA, Klett EL, Gylling H, Isoniemi H, Patel SB. Liver transplantation in a 
patient with sitosterolemia and cirrhosis. Gastroenterology 2006;130:542-547. 
 
Miettinen TA, Koivisto P. Non-cholesterol sterols and bile acid production in 
hypercholesterolemic patients with ileal by-pass. In: Paumgartner G, Stiehl A, 
Gerok W, eds. Bile acids and cholesterol in health and disease. Lanchaster, PA: 
MTP Press;1983:183-187. 
 
Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol 
precursors reflect cholesterol absorption and synthesis in volunteers of a 
randomly selected male population. Am J Epidemiol 1990;131:20-31. 
 
 101 
Miettinen TA, Tilvis RS, Kesäniemi YA. Serum cholestanol and plant sterol levels in 
relation to cholesterol metabolism in middle-aged men. Metabolism 1989;38:136-
140. 
 
Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid 
Res 1988;29:43-51. 
 
Millar AJ, Gupte G, Sharif K. Intestinal transplantation for motility disorders. Semin 
Pediatr Surg 2009;18:258-262. 
 
Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, Seres D, Guenter 
P; Task force for the revision of safe practices for parenteral nutrition. Safe 
practices for parenteral nutrition. J Parenter Enteral Nutr 2004;28:S39-S70. 
 
Misra S, Ament ME, Vargas JH, Skoff C, Reyen L, Herzog F. Chronic liver disease in 
children on long-term parenteral nutrition. J Gastroenterol Hepatol 1996;11:S4-6. 
 
Miyasaka EA, Brown PI, Kadoura S, Harris MB, Teitelbaum DH. The adolescent child 
with short bowel syndrome: new onset of failure to thrive and need for increased 
nutritional supplementation. J Pediatr Surg 2010;45:1280-1286. 
 
Modi BP, Langer M, Ching YA, Valim C, Waterford SD, Iglesias J, Duro D, Lo C, 
Jaksic T, Duggan C. Improved survival in a multidisciplinary short bowel 
syndrome program. J Pediatr Surg 2008;43:20-24. 
 
Montalto M, D’Onofrio, Santoro L, Gallo A, Gasbarrini A, Gasbarrini G. Autoimmune 
entheropathy in children and adults. Scand Jour Gastroenterol 2009;44:1029-
1036. 
 
Moss RL, Das JB, Raffensperger JG. Total parenteral nutrition-associated 
cholestasis: clinical and histopathologic correlation. J Pediatr Surg 1993;28:1270-
1275. 
 
Mullick FG, Moran CA, Ishak KG. Total parenteral nutrition: a histopathologic 
analysis of the liver changes in 20 children. Mod Pathol 1994;7:190-194. 
 
Mutanen A, Mäkitie O, Pakarinen MP. Risk of metabolic bone disease is increased 
both during and after weaning off parenteral nutrition in pediatric intestinal failure. 
Horm Res Paediatr 2013;79:227-235. 
 
Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: a 
histopathologic study with clinical correlation. Hum Pathol 2012;43:826-833. 
 
Nasr A, Avitzur Y, Ng VL, De Silva N, Wales PW. The use of conjugated 
hyperbilirubinemia greater than 100 micromol/L as an indicator of irreversible 
liver disease in infants with short bowel syndrome. J Pediatr Surg 2007;42:359-
362. 
 
Navarro F, Gleason WA, Rhoads JM, Quiros-Tejeira RE. Short bowel syndrome: 
epidemiology, pathophysiology and adaptation. NeoReviews 2009;10:e330-e338. 
 102
Ngo KD, Farmer DG, McDiarmid SV, Artavia K, Ament ME, Vargas J, Busuttil RW, 
Colangelo J, Esmailian, Gordon-Burroughs S, Duffy J, Venick RS. Pediatric 
health-related quality of life after intestinal transplantation. Pediatr Transplantation 
2011;15:849-854. 
 
Niinikoski H, Stoll B, Guan X, Kansagra K, Lambert BD, Stephens J, Hartmann B, 
Holst JJ, Burrin DG. Onset of small intestinal atrophy is associated with reduced 
intestinal blood flow in TPN-fed neonatal piglets. J Nutr 2004;134:1467-1474. 
 
Nikkilä K, Höckerstedt K, Miettinen TA. High cholestanol and low campesterol-to-
sitosterol ratio in serum of patients with primary biliary cirrhosis before liver 
transplantation. Hepatology 1991;13:663-669. 
 
Nikkilä K, Miettinen TA, Höckerstedt KV, Isoniemi H. Sterol parameters as markers of 
liver function in primary biliary cirrhosis before and after liver transplantation. 
Transpl Int 2005;18:221-225. 
 
Nikkilä K, Nissinen MJ, Gylling H, Isoniemi H, Miettinen TA. Serum sterols in patients 
with primary biliary cirrhosis and acute liver failure before and after liver 
transplantation. J Hepatol 2008;49:936-945. 
 
Nissinen MJ, Gylling H, Miettinen TA. Responses of surrogate markers of cholesterol 
absorption and synthesis to changes in cholesterol metabolism during various 
amounts of fat and cholesterol feeding among healthy men. Br J Nutr 
2008;99:370-378. 
 
Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with 
short bowel. Lancet 1994;343:373-376. 
 
Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support of energy 
absorption as small-bowel failure proceeds. Am J Clin Nutr 1996;64:222-231. 
 
O’Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. 
Short bowel syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol 2006;4:6-10. 
 
O’Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and 
efficacy of teduglutide after 52 weeks of treatment in patients with short bowel 
intestinal failure. Clin Gastroenterol Hepatol 2013;11:815-823. 
 
Olieman JF, Penning C, Spoel M, Ijsselstijn H, van den Hoonaard TL, Escher JC, 
Bax NM, Tibboel D. Long-term impact of infantile short bowel syndrome on 
nutritional status and growth. Br J Nutr 2012;107:1489-1497. 
 
Ozguner IF, Savas C, Ozguner M, Candir O. Intestinal atresia with segmental 
musculature and neural defect. J Pediatr Surg 2005; 40:1232-1237. 
 
Pakarinen MP, Koivusalo AI, Rintala RJ. Outcomes of intestinal failure –a 
comparison between children with short bowel and dysmotile intestine. J Pediatr 
Surg 2009;44:2139-2144. 
 103 
Pakarinen MP, Kurvinen A, Gylling H, Miettinen TA, Pesonen M, Kallio M, Koivusalo 
AI, Nissinen MJ. Cholesterol metabolism in pediatric short bowel syndrome after 
weaning off parenteral nutrition. Dig Liv Dis 2010;42:554-559. 
 
Pakarinen MP, Kurvinen A, Koivusalo AI, Iber T, Rintala RJ. Long-term controlled 
outcomes after autologous intestinal reconstruction surgery in treatment of severe 
short bowel syndrome. J Pediatr Surg 2013;48:339-344. 
 
Pakarinen MP, Kurvinen A, Koivusalo AI, Ruuska T, Mäkisalo H, Jalanko H, Rintala 
RJ. Surgical treatment and outcomes of severe pediatric intestinal motility 
disorders requiring parenteral nutrition. J Pediatr Surg 2013;48:333-338. 
 
Pakarinen MP, Lampela H, Gylling H, Miettinen TA, Koivusalo AI, Nissinen MJ. 
Surrogate markers of cholesterol metabolism in children with native liver after 
successful portoenterostomy for biliary atresia. J Pediatr Surg 2010;45:1659-
1664. 
 
Pálová S, Charvat J, Kvapil M. Comparison of soybean oil- and olive oil-based lipid 
emulsions on hepatobiliary function and serum triacylglycerols level during 
realimentation. J Int Med Res 2008;36:587–93. 
 
Panis Y, Messing B, Rivet P,  Coffin B, Hautefeuille P, Matuchansky C, Rambaud JC, 
Valleur P. Segmental reversal of the small bowel as an alternative to intestinal 
transplantation in patients with short bowel syndrome. Ann Surg 1997;225:401-
407. 
 
Peden VH, Witzleben CL, Skelton MA. Total parenteral nutrition. J Pediatr 
1971;78:180-181. 
 
Pereira GR, Sherman MS, DiGiacomo J, Ziegler M, Roth K, Jacobowski D. 
Hyperalimentation-induced cholestasis. Increased incidence and severity in 
premature infants. Am J Dis Child 1981;135:842-845. 
 
Peretti N, Loras-Duclaux I, Kassai B, Restier-Miron L, Guimber D, Gottrand F, 
Coopman S, Michaud L, Marinier E, Yantren H, Michalski MC, Aubert F, Mercier 
C, Pelosse M, Lopez M, Chatelain P, Lachaux A. Growth hormone to improve 
short bowel syndrome intestinal autonomy: a pediatric randomized open-label 
clinical trial. J Parenter Enteral Nutr 2011;35:723-731. 
 
Persemidis D, Kark AE. Antiperistaltic segments for the treatment of short bowel 
syndrome. Am J Gastroenterol 1974;62:526-530. 
 
Peterson CA, Carey HV, Hinton PL, Lo HC, Ney DM. GH elevates serum IGF-I levels 
but does not alter mucosal atrophy in parenterally fed rats. Am J Physiol 
1997;272:G1100-1108. 
 
Peyret B, Collardeau S, Touzet S, Loras-Duclaux I, Yantren H,  Michalski MC, Chaix 
J, Restier-Miron L, Bouvier R, Lachaux A, Peretti N. Prevalence of liver 
complications in children receiving long-term parenteral nutrition. Eur J Clin Nutr 
2011;65:743-749. 
 104
Pichler J, Horn V, MacDonald S, Hill S. Sepsis and its etiology among hospitalized 
children less than 1 year of age with intestinal failure on parenteral nutrition. 
Transplant Proc 2010;42:24-25. 
 
Pironi L, Goulet O, Buchman A, Messing B, Candusso M, Bond G, Gupte G, 
Pertkiewicz M, Steiger E, Forbes A, Van Gossum A, Pinna AD; Home artificial 
nutrition and chronic intestinal failure working group of ESPEN. Outcome on 
home parenteral nutrition for benign intestinal failure: a review of the literature and 
benchmarking with the European prospective survey of ESPEN. Clin Nutr 
2012;31:831-845. 
 
Pironi L, Hébuterne X, Van Gossum A, Messing B, Lyszkowska M, Colomb V, Forbes 
A, Micklewright A, Villares JM, Thul P, Bozzetti F, Goulet O, Staun M. Candidates 
for intestinal transplantation: a multicenter survey in Europe. Am J Gastroenterol 
2006;101:1633-1643. 
 
Pironi L, Paganelli F, Labate AM, Merli C, Guidetti C, Spinucci G, Miglioli M. Safety 
and efficacy of home parenteral nutrition for chronic intestinal failure: a 16-year 
experience at a single centre. Dig Liver Dis 2003;35:314-324. 
 
Postuma R, Trevenen CL. Liver disease in infants receiving total parenteral nutrition. 
Pediatrics 1979;63:110-115. 
 
Potter C, Hogan MJ, Henry-Kendjorsky K, Balint J, Barnard JA. Safety of pediatric 
percutaneous liver biopsy performed by interventional radiologist. J Pediatr 
Gastroenterol Nutr 2011;53:202-206. 
 
Pozo J, Argente J. Delayed puberty in chronic illness. Best Pract Clin Endocrinol 
Metab 2002;16:73-90. 
 
Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan 
C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral 
nutrition-associated liver injury. Ann Surg 2009;250:395–402. 
 
Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total 
parenteral nutrition. Gastroenterology 1993;104:286-301. 
 
Quirós-Tejeira RE, Ament ME, Reyen L, Herzog F, Merjanian M, Olivares-Serrano N, 
Vargas JH. Long-term parenteral nutrition support and intestinal adaptation in 
children with short bowel syndrome: a 25-year experience. J Pediatr 
2004;145:157-163. 
 
Rager R, Finegold MJ. Cholestasis in immature newborn infants: is parenteral 
alimentation responsible? J Pediatr 1975;86:264-269. 
 
Randall HT. Sixth annual Jonathan E. Rhoads lecture. Enteral nutrition: tube feeding 
in acute and chronic illness. J Parenter Enteral Nutr 1984:8:113-136. 
 
Robinson DT, Ehrenkranz RA. Parenteral nutrition-associated cholestasis in small for 
gestational age infants. J Pediatr 2008;152:59-62. 
 105 
Rodgers BM, Hollenbeck JI, Donnelly WH, Talbert JL. Intrahepatic cholestasis with 
parenteral alimentation. Am J Surg 1976;131:149-155. 
 
Rodriguez L, Nurko S. Motility disorders in intestinal failure. In: Duggan CP, Gura M, 
Jaksic T, editors. Clinical management of intestinal failure, 1st ed. Boca Raton: 
CRC Press; 2012. p.31-46. 
 
Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, Di 
Lorenzo C, Flores AF, Hillemeier AC, McCallum RW, Vanderhoof JA. Diagnosis 
and treatment of chronic intestinal pseudo-obstruction in children: report of 
consensus workshop. J Pediatr Gastroenterol Nutr 1997;24:102-112. 
 
Russel DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev 
Biochem 2003;72:137-174. 
 
Saari A, Sankilampi U, Hannila ML, Kiviniemi V, Kesseli K, Dunkell L. New Finnish 
growth references for children and adolescents ages 0 to 20 years: Length/height-
for-age, weight-for-length/height, and body mass index-for-age. Ann Med 
2011;43:235-248. 
 
Salen G, Shefer S, Nguyen L, Ness GC, Tint GS, Shore V. Sitosterolemia. J Lipid 
Res 1992;33:945-955. 
 
Salvia G, Guarino A, Terrin G, Cascioli C, Paludetto R, Indrio F, Lega L, Fanaro S, 
Stronati M, Corvaglia L, Tagliabue P, De Curtis M; Working group on neonatal 
gastroenterology of the Italian society of pediatric gastroenterology, hepatology 
and nutrition. Neonatal onset intestinal failure: an Italian multicenter study. J 
Pediatr 2008;153:674-676. 
 
Schalamon J, Mayr JM, Höllwarth ME. Mortality and economics in short bowel 
syndrome. Best Pract Res Clin Gastroenterol 2003;17:931-942. 
 
Scheuer PJ, Lefcowitch PJ. Assessment and differential diagnosis of pathological 
features. In: Scheuer PJ, Lefcowich PJ, eds. Liver biopsy interpretation. Volume 
1, 7th ed. Philadelphia, PA: Elsevier Saunders;2006:35-51. 
 
Scheuer PJ, Lefkowitch PJ. Steatosis and steatohepatitis. In:Scheuer PJ, Lefkowitch 
PJ, eds. Liver biopsy interpretation. Volume 1, 7th ed. Philadelphia, PA: Elsevier 
Saunders;2006:105-123. 
 
Scolapio JS. Treatment of short bowel syndrome. Curr Opin Clin Nutr Metab Care 
2001;4:557-560. 
 
Sham J, Martin G, Meddings JB, Sigalet DL. Epidermal growth factor improves 
nutritional outcome in a rat model of short bowel syndrome. J Pediatr Surg 
2002;37:765-769. 
 
Sheldon GF, Peterson SR, Sanders R. Hepatic dysfunction during hyperalimentation. 
Arch Surg 1978;113:504-508. 
 
 106
Shou J, Lappin J, Minnard EA, Daly JM. Total parenteral nutrition, bacterial 
translocation, and host immune function. Am J Surg 1994;167:145-150. 
 
Shulman DI, Hu CS, Duckett G, Lavallee-Grey M. Effects of short-term growth 
hormone therapy in rats undergoing 75% small intestinal resection. J Pediatr 
Gastroenterol Nutr 1992;14:3-11. 
 
Shulman RJ. New developments in total parenteral nutrition for children. Curr 
Gastroenterol Rep 2000;2:253-258. 
 
Simon D. Puberty in chronically diseased patients. Horm Res 2002;57:53-56. 
 
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted 
distribution of the nuclear receptor FXR/BAR impairs bile acid and lipid 
homeostasis. Cell 2000;102:731-744. 
 
Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal 
fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with 
irreversible intestinal failure. J Pediatr 2010;156:327-331. 
 
Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in 
neonates with intestinal resection and long-term parenteral nutrition. J Pediatr 
Gastroenterol Nutr 1998;27:131-137. 
 
Spencer AU, Kovacevich D, McKinney-Barnett M, Hair D, Canham J, Maksym C, 
Teitelbaum DH. Pediatric short bowel syndrome: the cost of comprehensive care. 
Am J Clin Nutr 2008;88:1552-1559. 
 
Spencer AU, Neaga A, West B, Safran J, Brown P, Btaiche I, Kuzma-O’Reilly B, 
Teitelbaum DH. Pediatric short bowel syndrome: redefining predictors of success. 
Ann Surg 2005;242:403-409. 
 
Spencer AU, Yu S, Tracy TF, Aouthmany MM, Llanos A, Brown MB, Brown M, 
Shulman RJ, Hirschl RB, Derusso PA, Cox J, Dahlgren J, Strouse PJ, Groner JI, 
Teitelbaum DH. Parenteral nutrition-associated cholestasis in neonates: 
multivariate analysis of the potential effect of taurine. J Parenter Enteral Nutr 
2005;29:337-343. 
 
Squires RH, Duggan C, Teitelbaum DH, Wales PW, Balint J, Venick R, Rhee S, 
Sudan D, Mercer D, Martinez JA, Carter BA, Soden J, Horslen S, Rudolph JA, 
Kocoshis S, Superina R, Lawlor S, Haller T, Kurs-Lasky M, Belle SH. Natural 
history of pediatric intestinal failure: initial report from the pediatric intestinal 
failure consortium. J Pediatr 2012;161:723-728. 
 
Stacchini A, Didio LJ, Primo ML, Andretto R. Artificial sphincter as surgical treatment 
for experimental massive resection of small intestine. Am J Surg 1982;143:721-
726. 
 
Staun M, Pironi L, Bozetti F, Baxter J, Forbes A, Joly F, Jeppesen P, Moreno J, 
Hébuterne X, Pertkiewicz, Mühlebach S, Shenkin A, Van Gossum A. ESPEN 
 107 
Guideline on parenteral nutrition: home parenteral nutrition (HPN) in adult 
patients. Clin Nutr 2009;28:467-479. 
 
Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. 
Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 
2009;32:126-128. 
 
Struijs MC, Diamond IR, de Silva N, Wales PW. Establishing norms for intestinal 
length in children. J Pediatr Surg 2009;44:933-938. 
 
Stultz JS, Tillman E, Helms RA. Plasma citrulline as a biomarker for bowel loss and 
adaptation in hospitalized pediatric patients requiring parenteral nutrition. Nutr 
Clin Pract 2011;26:681-687. 
 
Sudan D, DiBaise J, Torres C, Thompson J, Raynor S, Gilroy R, Horslen S, Grant W, 
Botha J, Langnas A. A multidisciplinary approach to the treatment of intestinal 
failure. J Gastrointest Surg 2005;9:165-176. 
 
Sudan D, Horslen S, Botha J, Grant W, Torres C, Shaw B Jr, Langnas A. Quality of 
life after pediatric intestinal transplantation: the perception of pediatric recipients 
and their parents. Am J Transplant 2004;4;407-413. 
 
Sudhop T, Sahin Y, Lindenthal B, Hahn C, Lüers C, Berthold HK, von Bergmann K. 
Comparison of the hepatic clearances of campesterol, sitosterol, and cholestenol 
in healthy subjects suggest that efflux transporters controlling intestinal sterol 
absorption also regulate biliary secretion. Gut 2002;51:860-863. 
 
Tanner J. Growth at adolescence. Oxford 1962: Blackwell Scientific Publication. 
 
Tazuke Y, Teitelbaum DH. Alterations of canalicular transporters in a mouse model 
of total parenteral nutrition. J Pediatr Gastroenterol Nutr 2009;48:193-202. 
 
Teitelbaum DH, Tracy TF, Aouthmany MM, Llanos A, Brown MB, Yu S, Brown MR, 
Shulman RJ, Hirschl RB, Derusso PA, Cox J, Dahlgren J, Groner JI, Strouse PJ. 
Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-
associated cholestasis. Pediatrics 2005;115:1332-1340. 
 
Thompson JS. Overview of etiology and management on intestinal failure. 
Gastroenterology 2006;130:S3-4. 
 
Tillman EM. Review and clinical update on parenteral nutrition-associated liver 
disease. Nutr Clin Pract 2013;28:30-39. 
 
Topstad D, Martin G, Sigalet D. Systemic GLP-2 levels do not limit adaptation after 
distal intestinal resection. J Pediatr Surg 2001;36:750-754. 
 
Torres C, Sudan D, Vanderhoof J, Grant W, Botha J, Raynor S, Langnas A. Role of 
an intestinal rehabilitation program in the treatment of advanced intestinal failure. 
J Pediatr Gastroenterol Nutr 2007;45:204-212. 
 
 108
Touloukian RJ, Downing SE. Cholestasis associated with long-term parenteral 
hyperalimentation. Arch Surg 1973;106:58-62. 
 
Touloukian RJ, Smith GJ. Normal intestinal length in preterm infants. J Pediatr Surg 
1983;18:720-723. 
 
Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 
1998;339:1217-1227. 
 
Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic 
model assessment (HOMA) index cut-off values to identify the metabolic 
syndrome in children. J Physiol Biochem 2005;61:381-388. 
 
Ulshen MH, Dowling RH, Fuller CR, Zimmermann EM, Lund PK. Enhanced growth of 
small bowel in transgenic mice overexpressing bovine growth hormone. 
Gastroenterology 1993;104:973-980. 
 
van Gossum A, Bakker H, De Francesco A, Ladefoged K, Leon-Sanz M, Messing B, 
Pironi L, Pertkiewicz M, Shaffer J, Thul P, Wood S. Home parenteral nutrition in 
adults: a multicentre survey in Europe in 1993. Clin Nutr 1996;15:53-59. 
 
Vanderwinden JM, Rumessen JJ, Liu H, Descamps D, de Laet MH, Vanderhaeghen 
JJ. Intestinal cells of Cajal in human colon and in Hirschsprung’s disease. 
Gastroenterology 1996;111:901-910. 
 
Vileisis RA, Sorensen K, Gonzalez-Crussi F, Hunt CE. Liver malignancy after 
parenteral nutrition. J Pediatr 1982;100:88-90. 
 
Wada M, Nishi K, Nakamura M, Kudo H, Yamaki S, Sasaki H, Sato T, Fukuzawa T, 
Tanaka H, Kazama T, Amae S, Nio M. Life-threatening risk factors and the role of 
intestinal transplantation in patients with intestinal failure. Pediatr Surg Int 
2013;29:1115-1118. 
 
Waddell WR, Kern F, Halgrimson CG, Woodbury JJ. A simple jejunocolic “valve”. For 
relief of rapid transit and the short bowel syndrome. Arch Surg 1970;100:438-444. 
 
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, 
Lok AS. A simple noninvasive index can predict both significant fibrosis and 
cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526. 
 
Wales PW, Christison-Lagay ER. Short bowel syndrome: epidemiology and etiology. 
Semin Pediatr Surg 2010;19:3-9. 
 
Wales PW, de Silva N, Kim J, Lecce L, To T, Moore A. Neonatal short bowel 
syndrome: population based estimates of incidence and mortality rates. J Pediatr 
Surg 2004;39:690-695. 
 
Wales PW, de Silva N, Kim JH, Lecce L, Sandhu A, Moore AM. Neonatal short bowel 
syndrome: a cohort study. J Pediatr Surg 2005;40:755-762. 
 
 109 
Wallander J, Ewald U, Läckgren G, Tufveson G, Wahlberg J, Meurling S. Extreme 
short bowel syndrome in neonates: an indication for small bowel transplantation? 
Transplant Proc 1992;24:1230-1235. 
 
Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are 
ligands for the nuclear receptor FXR/BAR. Molecular Cell 1999;3:543–53. 
 
Wang H, Khaoustov VI, Krishnan B, Cai W, Stoll B, Burrin DG, Yoffe B. Total 
paranteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J 
Nutr 2006;136:2547-2552. 
 
Watkins JB, Szczepanik P, Gould JB. Lester R. Bile salt metabolism in the human 
premature infant. Preliminary observations of pool size and synthesis rate 
following prenatal administration of dexametasone and phenobarbital. 
Gastroenterology 1975;69:706-713. 
 
Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel 
syndrome. Semin Perinatol 2007;31:104-111. 
 
Williams NS, Evans P, King RF. Gastric acid secretion and gastrin production in the 
short bowel syndrome. Gut 1985;26:914-919. 
 
Wilmore DW, Dudrick SJ. Growth and development of an infant receiving all nutrients 
exclusively by vein. JAMA 1968;203:860-864. 
 
Wilmore DW. Growth factors and nutrients in short bowel syndrome. J Perenter Enter 
Nutr 1999;23:S117-120. 
 
Wolf A, Pohlandt  F. Bacterial infection: the main cause of acute cholestasis in 
newborn receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr 
1989;8:297-303. 
 
Wolfe BM, Walker BK, Shaul DB, Wong L, Ruebner BH. Effect of total parenteral 
nutrition on hepatic histology. J Arch Surg 1988;123:1084-1090. 
 
Wretlind A. Recollections of pioneers in nutrition: landmarks in the development of 
parenteral nutrition. J Am Coll Nutr 1992;11:366-373. 
 
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li 
YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. 
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy 
expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 
2009;58:250-259. 
 
Yang H, Feng Y, Sun X, Teitelbaum DH. Enteral versus parenteral nutrition: effect on 
intestinal barrier function. Ann N Y Acad Sci 2009;1165:338-346. 
 
Yang H, Finaly R, Teitelbaum DH. Alteration in epithelial permeability and ion 
transport in a mouse model of total parenteral nutrition. Crit Care Med 
2003;31:1118-1125. 
 110
Yeop I, Taylor C, Narula P, Johnson L, Bowen C, Gupte G. Hepatocellular carcinoma 
in a child with intestinal failure associated liver disease. J Pediatr Gastroenterol 
Nutr 2012;5:695-697. 
 
Youssef NN, Mezoff AG, Carter B, Cole CR. Medical update and potential advances 
in the treatment of pediatric intestinal failure. Curr Gastroenterol Rep 
2012;14:243-252. 
 
Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, Jia W, Xu A. 
Circadian rhythm of circulation fibroblast growth factor 21 is related to diurnal 
changes in fatty acids in humans. Clin Chem 2011;57:691-700. 
 
Zambrano E, El-Hennawy M, Ehrenkranz RA, Zelterman D, Reyes-Múgica M. Total 
parenteral nutrition induced liver pathology: an autopsy series of 24 newborn 
cases. Pediatr Dev Pathol 2004;7:425-432. 
 
Zhang W, Li N, Zhu W, Shi Y, Zhang J, Li Q, Li J. Peptide YY induces enterocyte 
proliferation in a rat model with total enteral nutrition after distal bowel resection. 
Pediatr Surg Int 2008;24:913-919. 
 
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, 
Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are 
independently associated with metabolic syndrome in humans. Diabetes 
2008;57:1246-1253. 
 
Zhu W, Zhang W, Gong J, Huang Q, Shi Y, Li Q, Li N, Li J. Peptide YY induces 
intestinal proliferation in peptide YY knockout mice with total enteral nutrition after 
massive small bowel resection. J Pediatr Gastroenterol Nutr 2009;48:517-525. 
